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ABSTRACT 
Acute pancreatitis (AP) is a common gastrointestinal disease of varying 
severity. While mild AP is a local inflammation of the pancreas that resolves 
within days, in severe AP (SAP) systemic inflammatory response is 
comparable to that seen in bacterial sepsis, leading to persistent organ 
dysfunction (OD), which is associated with substantial morbidity and 
mortality. However, in half of the SAP patients, the clinical signs of OD are not 
yet present on admission to hospital, potentially delaying the diagnosis of SAP 
and the initiation of maximal supportive care, thus worsening the prognosis.  
The aims of this study were (i) to identify early predictive markers of SAP 
among patients with no OD on admission to hospital and (ii) to elucidate the 
aberrations in blood leukocyte signaling pathways in the early phase of AP and 
sepsis, which could reveal novel predictive markers of OD.  
This clinical study consists of four prospective studies. All AP patients 
investigated were admitted to Helsinki University Hospital within 72 or 96 
hours of onset of symptoms during the years 2003-2008 (Studies I and III), 
2011-2014 (Study II), and 2010-2012 (Study IV). The fourth study includes 
also patients with sepsis. In the first study, the serum levels of 48 circulating 
cytokines were assessed on hospital admission in 163 AP patients using the 
Multiplex detection technique. Of SAP patients, 14/25 had no OD on 
admission. In the second study, the admission plasma levels of interleukin 
(IL)-8 and hepatocyte growth factor (HGF) were analyzed using cytokine-
specific enzyme-linked immunosorbent assay (ELISA) in an independent 
cohort of 176 AP patients and 32 healthy controls. Of SAP patients, 10/23 had 
no OD on admission. In the third study, the admission plasma levels of 
nucleosomes were evaluated using ELISA in 74 AP patients. Of SAP patients, 
14/24 had no OD on admission. In the fourth study, the phosphorylation of 
nuclear factor kappa B (NF-ĸB), signal transducers and activators of 
transcription (STATs) 1 and 3, and extracellular signal-regulated kinase (ERK) 
1/2 mitogen-activated protein kinases (MAPK) were examined in 
appropriately stimulated or non-stimulated circulating leukocytes of 18 
patients with AP, 14 patients with sepsis, and 28 healthy controls using 
phosphospecific whole-blood flow cytometry.  
Our results show that IL-8, HGF, granulocyte colony-stimulating factor (G-
CSF), and nucleosomes are associated with the severity of AP and predict 
development of SAP among AP patients without OD on admission. The result 
concerning IL-8 and HGF was confirmed in a second study, which also shows 
that among patients with OD on admission IL-8 may predict persistent OD, 
i.e. SAP. The discovered signaling aberrations in NF-ĸB, STAT1, STAT3, and 
ERK1/2 MAPK pathways are largely similar in sepsis and SAP. However, only 
the results concerning STAT1 and STAT3 are associated with the severity of 
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AP. Additionally, STAT3 distinguishes patients with persistent OD (i.e. sepsis 
and SAP) from those without OD (i.e. mild and moderately severe AP).  
In conclusion, circulating levels of IL-8 and HGF may serve as useful 
predictors of SAP in AP patients without OD on admission. Additionally, G-
CSF and nucleosomes may predict development of SAP. Among patients with 
OD on admission, IL-8 may predict persistent OD. Signaling aberrations of 
circulating leukocytes in sepsis resemble those discovered in SAP. Aberrations 
in STAT1 and STAT3 pathways associate with the severity of AP and those in 
STAT3 with the presence of OD. Possibility that aberrations in STAT1 and 
STAT3 pathways provide novel markers for predicting development of OD 
warrants further studies. Early and accurate identification of patients at risk 
for SAP or OD may improve their prognosis. Additionally, such early markers 
may help to identify individual patients that will potentially benefit from 
immunomodulatory treatment modalities in the future.  
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TIIVISTELMÄ 
Akuutti haimatulehdus on yksi yleisimmistä diagnooseista 
vatsaelinkirurgisella päivystysosastolla. Sen yleisimmät aiheuttajat ovat 
alkoholinkäyttö ja sappikivitauti. Vaikka suurin osa akuuteista 
haimatulehduksista rauhoittuu muutamassa päivässä, noin 20 % 
haimatulehduksista komplisoituu. Vaikeasta haimatulehduksesta puhutaan, 
kun sen aiheuttama elinvaurio kestää yli 48 tuntia. Kuolleisuus vaikeaan 
haimatulehdukseen on jopa 15-59 %.  
Akuutti haimatulehdus aiheuttaa ensin haiman paikallisen 
tulehdusreaktion, joka vaikeassa haimatulehduksessa voimistuu ja etenee 
koko elimistön yleistyneeksi tulehdusreaktioksi aiheuttaen elinvaurion 
esimerkiksi keuhkoihin tai munuaisiin. Systeeminen tulehdusreaktio ja sen 
aiheuttamat elinvauriot kehittyvät vaikeassa haimatulehduksessa ainakin osin 
samoilla mekanismeilla kuin esimerkiksi sepsiksessä. Vaikeaa 
haimatulehdusta sairastavat potilaat hyötyvät voinnin tarkasta 
monitoroinnista sekä mahdollisimman varhaisesta tehokkaan nestehoidon 
aloituksesta. Näiden potilaiden tunnistaminen pian oireiden alkamisen 
jälkeen on kuitenkin haastavaa, sillä vain noin puolella havaitaan kliiniset 
elinvaurion merkit jo sairaalaan tullessa. 
Tämän väitöskirjatyön tavoitteena oli löytää verestä merkkiaineita, joilla 
vaikean haimatulehduksen kehittyminen voitaisiin ennustaa jo taudin 
varhaisvaiheessa ennen elinvaurion kliinisten merkkien ilmaantumista. 
Lisäksi selvitimme, tapahtuuko sepsispotilaiden veren valkosolujen 
signaalireiteissä vastaavia aktiivisuuden muutoksia kuin vaikeaa 
haimatulehdusta sairastavilla, ja voidaanko näiden avulla ennustaa 
elinvaurion kehittymistä. 
Tutkimus koostuu neljästä osatyöstä, joiden potilasrekrytointi suoritettiin 
Meilahden sairaalan päivystysalueella vuosina 2003-2008 (osatyöt I ja III), 
2011-2014 (osatyö II) ja 2010-2012 (osatyö IV). Tutkimukseen otetuilla 
potilailla oli diagnosoitu akuutti haimatulehdus, ja oireiden alusta oli aikaa 
alle 72 tai 96 tuntia. Osatyössä I analysoitiin Multiplex-menetelmällä 48 
sytokiinin seerumipitoisuudet 163 potilaalta, joista 25:lla oli vaikea 
haimatulehdus, mutta 14/25:lla ei ollut tulovaiheessa elinvauriota.  Osatyössä 
II analysoitiin ELISA-menetelmällä plasman interleukiini (IL) 8 -pitoisuus ja 
maksasolujen kasvutekijä (HGF) -pitoisuus uudessa potilasaineistossa 
(n=176; 10/23:lla vaikeista haimatulehduksista ei ollut tulovaiheessa 
elinvauriota) sekä 32 terveellä verrokilla. Osatyössä III analysoitiin ELISA-
menetelmällä plasman nukleosomipitoisuus 74 potilaalta (14/24:lla vaikeista 
haimatulehduksista ei ollut tulovaiheessa elinvauriota). Osatyössä IV 
analysoitiin virtaussytometriaan perustuvalla menetelmällä 18 
haimatulehduspotilaan, 14 sepsispotilaan sekä 28 terveen verrokin verestä 
valkosolujen eräiden yleisimpien tulehdussignalointireittien (NF-ĸB, ERK1/2 
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MAP-kinaasi, STAT1 ja STAT3), aktiivisuus sekä aktiivisuuden muutokset 
solujen stimulaation jälkeen.  
Tulokset osoittavat, että vaikeaa haimatulehdusta ennustavat ennen 
elinvaurion merkkien ilmaantumista IL-8, HGF, granulosyyttikasvutekijä (G-
CSF) sekä nukleosomit. Lisäksi potilailla, joilla on elinvaurio sairaalaan 
tullessa, IL-8 voi ennustaa elinvaurion pitkittynyttä (≥48 tuntia) kestoa. 
Havaitut muutokset tutkituissa valkosolujen signaalireittien aktiivisuudessa 
ovat samansuuntaisia sepsiksessä sekä vaikeaa haimatulehdusta sairastavilla. 
Kuitenkin vain muutokset STAT1 ja STAT3 signalointireiteissä näyttävät 
korreloivan akuutin haimatulehduksen vaikeusasteen kanssa. Lisäksi STAT3 
voi olla käyttökelpoinen erottamaan elinvaurio-potilaat (sepsis tai vaikea 
akuutti haimatulehdus) ei-elinvaurio-potilaista (lievä tai keskivaikea akuutti 
haimatulehdus). 
Yhteenvetona voidaan todeta, että IL-8 ja HGF toimivat kahdessa 
erillisessä potilasaineistossa vaikean haimatulehduksen ennustajina ennen 
elinvaurion merkkien ilmaantumista, ja täten ne saattavat toimia 
käyttökelpoisina vaikean haimatulehduksen merkkiaineina taudin 
alkuvaiheessa. Näiden lisäksi G-CSF ja nukleosomit saattavat ennustaa 
vaikean haimatulehduksen kehittymistä ennen elinvaurion merkkien 
ilmaantumista. Tutkituista valkosolujen signalointireiteistä STAT1 ja STAT3 
korreloivat haimatulehduksen vaikeusasteen, ja STAT3 elinvaurion, kanssa. 
Lisätutkimuksia tarvitaan selvittämään voisivatko STAT1 ja STAT3 toimia 
hyvin varhaisina elinvaurion ennustajina. Varhaisten merkkiaineiden avulla 
voitaisiin löytää riskipotilaat ajoissa ja täten parantaa taudin ennustetta sekä 
löytää se potilasryhmä, joka voisi hyötyä tällä hetkellä vielä kokeellisesta 
immuunivasteeseen vaikuttavasta täsmähoidosta.   
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1 INTRODUCTION 
Acute pancreatitis (AP) is a common gastrointestinal inflammatory disease 
induced by toxic factors such as alcohol or biliary stones. The early events that 
take place in the pancreas include early activation of pancreatic proteases, 
resulting in acinar cell injury and subsequent release of damage-associated 
molecular patterns (DAMPs) that activate the innate immune system (Kang et 
al. 2014a). In parallel with these events, the nuclear factor kappa B (NF-ĸB) 
pathway is activated in the pancreas, leading to production of 
proinflammatory cytokines and chemokines (Rakonczay et al. 2008). 
Consequently, recruitment of monocytes, neutrophils, and lymphocytes into 
the pancreas occurs.  
The severity of AP varies from mild to severe. In severe AP (SAP), the initial 
local inflammatory reaction amplifies and spreads through the circulation to 
produce a severe systemic response complicated by organ dysfunction (OD) 
that is associated with substantial morbidity and mortality (Norman 1998, 
Kylänpää et al. 2012). It has been shown that the evolution of systemic 
inflammation is similar in SAP and sepsis, with a similar pattern of released 
inflammatory mediators and comparable clinical symptoms, which are a 
consequence of an uncontrolled acute inflammatory response of the host 
(Deitch 1992, Wilson et al. 1998). Simultaneously with the proinflammatory 
response, an anti-inflammatory response ensues, which may lead to excessive 
immune suppression, complicating the course of both diseases (Kylänpää et 
al. 2012, Hotchkiss et al. 2013).  
In SAP, the evolution of systemic inflammation and subsequent 
development of multiple organ dysfunction syndrome (MODS) may occur 
rapidly, within the first few days or even hours (McKay and Buter 2003). 
Therefore, identifying AP patients who will develop SAP but who do not have 
clinical signs of OD on admission to hospital is crucial to minimize the delay 
in initiating optimal supportive treatment and intensive monitoring, which 
may improve their prognosis (Haydock et al. 2013). In the future, these SAP 
patients may also be an optimal target for immunomodulatory treatment 
modalities. However, predicting SAP on admission is complex. If a patient 
presents early after symptom onset, it is possible that OD signs have not yet 
developed. On the other hand, not all patients who present with OD will 
develop SAP (Wilson et al. 1990, Buter et al. 2002). Therefore, a reliable 
laboratory marker or a combination of markers is needed to support the 
clinical judgment.  
The main purpose of the present investigation was to identify predictors of 
SAP in AP patients without OD on admission. Although predictive markers of 
SAP have been assessed extensively (Brivet et al. 1999, Mentula et al. 2005, 
Aoun et al. 2009), as a novel approach, we focused on AP patients showing no 
signs of OD on admission, which we think, reveals the true ability of the 
INTRODUCTION 
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markers to predict SAP. In more detail, we evaluated 48 circulating cytokines 
as well as circulating nucleosomes on admission to hospital as potential 
biomarkers in predicting development of SAP. Additionally, the ability of the 
markers to predict persistent OD, i.e. SAP, in patients with OD on admission 
was analyzed. Finally, in search for potential early predictors of OD, the 
aberrations in the activity of the major inflammation-associated leukocyte 
signaling pathways, including NF-ĸB, signal transducers and activators of 
transcription (STATs) 1 and 3, and extracellular signal-regulated kinase (ERK) 
1/2 mitogen-activated protein kinases (MAPK), during AP and sepsis were 
investigated to determine whether the aberrations are similar in sepsis and 
SAP and whether they are associated with the severity of AP and the presence 
of OD.  
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2 REVIEW OF THE LITERATURE 
2.1 EPIDEMIOLOGY AND ETIOLOGY OF ACUTE 
PANCREATITIS  
Worldwide, the incidence of AP is increasing (Hamada et al. 2014, Krishna et 
al. 2017, Roberts et al. 2017), and in the United States AP is the third most 
common reason for hospital admission among gastrointestinal problems 
(Peery et al. 2015). The incidence of AP varies across countries and different 
regions. Among 17 European countries, the incidence ranges from 4.6 to 100 
per 100 000 and is highest (> 40 per 100 000) in eastern and northern 
countries and lowest in Albania (Roberts et al. 2017). High incidence rates (> 
40 per 100 000) have also been reported in USA (Frey et al. 2006), Japan 
(Hamada et al. 2014), and Taiwan (Shen and Lu 2011). The incidence in 
Finland, based on a study from 1989 in the Tampere region, is as high as 73 
per 100 000 (Jaakkola and Nordback 1993).  
Equal proportions of men and women develop AP, and the risk of AP 
progressively increases with age, but age and sex distributions differ based on 
etiology. Of lifestyle factors, alcohol consumption and smoking are 
associated with an elevated risk of AP, and obesity increases both the risk and 
severity of AP (Yadav and Lowenfels 2013). The proportions of different 
etiologic factors vary across countries and regions, but the three most common 
etiologic factors of AP are alcohol consumption, gallstones, and idiopathic 
AP. In European countries, gallstones are the underlying cause in 19-65% of 
cases and alcohol in 4-56% of cases (Roberts et al. 2017). In Finland, alcohol 
is the most common etiology in more than half of the episodes, whereas 
gallstones explain 20% (Mentula et al. 2003, Khan et al. 2013). However, the 
risk of biliary pancreatitis is not more than 2% in patients with asymptomatic 
gallstones, and the risk of alcoholic pancreatitis in heavy drinkers is unlikely 
to exceed 2-3% (Lankisch et al. 2002). Therefore, other factors, possible 
genetic, are also involved in triggering AP (Whitcomb 2013).  
Other known etiologic factors are rare and include medical treatments, 
with more than 130 drugs reported to be associated with AP. However, the true 
causal role is lacking in the vast majority of drugs, and therefore, before 
suggesting a drug as the cause of AP, a careful evaluation of more common 
causes is recommended (Tenner 2014). Hypertriglyceridemia should be 
suspected in a patient with known genetic abnormality of lipoprotein 
metabolism or presenting with secondary factors such as uncontrolled 
diabetes, alcoholism, use of medications known to cause hypertriglyceridemia, 
and the third trimester of pregnancy. Triglyceride level ≥ 13 mmol/L indicates 
a high degree of suspicion of hypertriglyceridemia-induced AP (Scherer et al. 
2014). The triglyceride level should be determined within 24 hours of 
presentation since fasting lowers the levels quickly. Hypercalcemia caused 
Review of the literature 
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by e.g. hyperparathyreoidism, malignant diseases, and overdose of vitamin D 
or calcium is associated with AP, and therefore, calcium levels should be 
determined on admission (Kemppainen and Puolakkainen 2007). 
Autoimmune pancreatitis has typical morphologic features in contrast-
enhanced computed tomography (CECT) and is usually an issue in the 
differential diagnosis between pancreatic tumor and chronic pancreatitis, 
rather than AP (Okazaki 2002). Especially in older patients with an unknown 
etiology of AP, the possibility of a tumor obstructing the ampullary region 
must be considered (Mujica et al. 2000).  
Pancreas divisum, an anatomic variation of pancreatic duct resulting 
from the failure of fusion of the dorsal and ventral pancreatic buds during 
gestation, has been reported in 5-7% of the general population and is 
associated with an increased risk of AP. According to current knowledge, 
pancreas divisum does not cause AP alone, but is associated with genetic 
mutations, producing a cumulative effect (Bertin et al. 2012). Another much 
debated underlying factor is Sphincter Oddi’s dysfunction (Cote et al. 
2012, Romagnuolo 2013).  
The risk of AP is also associated with invasive procedures. The 
frequency of AP after endoscopic retrograde cholangiopancreatography 
(ERCP) is 3.5% in unselected patients. Definite patient-related risk factors 
include suspected sphincter of Oddi dysfunction and female sex (Dumonceau 
et al. 2010). The risk is 0.85% after endoscopic ultrasound-guided fine needle 
aspiration of solid pancreatic mass (Eloubeidi et al. 2006) and up to 1% after 
single-balloon or double-balloon enteroscopy. It is of note that unspecific 
hyperamylasemia is seen in 16-17% of cases after single-balloon or double-
balloon enteroscopy, probably due to repeated stretching of the small bowel or 
mesenteric ligaments (Lankisch et al. 2015). In addition, AP is associated with 
the postoperative phase of surgery. Abdominal trauma, mild, blunt, 
or sharp, may cause AP. Similarly, AP may follow abdominal operations, 
and an association between cardiac surgery and AP has been noted 
(Kemppainen and Puolakkainen 2007, Forsmark et al. 2016). Certain viruses 
(cytomegalovirus, mumps, Epstein-Barr virus) and parasites are also rare 
etiologic factors.  
Finally, in many cases the etiology of AP remains unknown and is defined 
as idiopathic. The acceptable rate of idiopathic AP is < 20% (Working Party of 
the British Society of Gastroenterology 2005). 
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2.2 PATHOGENESIS AND PATHOPHYSIOLOGY OF 
ACUTE PANCREATITIS 
2.2.1 TRIGGERING FACTORS 
 
Mechanisms by which different etiologic factors, such as alcohol and 
gallstones, induce pancreatic cell injury and initiate AP include multiple 
pathobiologic pathways in acinar cells, but recent studies show also ductal 
cells as important participants in AP (Hegyi et al. 2011, Hegyi and Rakonczay 
2015).  However, the exact pathogenetic mechanisms are not fully understood.  
Ethanol is metabolized via oxidative and non-oxidative pathways. 
Although the products of ethanol metabolism (acetaldehyde, oxidative stress, 
and fatty acid ethyl esters) have the capacity to injure the pancreas, recent 
studies show that especially fatty acid ethyl esters, the metabolite of the non-
oxidative pathway, play a critical role in mediating alcohol-related pancreatic 
injury and inflammation (Apte et al. 2010, Hegyi et al. 2011). Within 
pancreatic ducts alcohol increases the formation of protein plugs that enlarge 
and form calculi leading eventually to acinar cell atrophy and fibrosis. Alcohol 
exerts toxic effects also on pancreatic stellate cells (Apte et al. 2010).   
 Transient pancreatic duct outflow obstruction is currently considered the 
initiating factor in biliary AP (Lerch et al. 1994). Duct obstruction may 
originate from refluxed bile acids, pancreatic duct hypertension, and/or 
aberrant acinar cell secretion (Lightner and Kirkwood 2001). Additionally, bile 
acids have direct toxic effects on acinar cells, where they elicit intracellular 
calcium release and subsequent cell injury and inflammation (Voronina et al. 
2002, Hegyi et al. 2011). Bile acids can be taken up by acinar cells from the 
pancreatic duct through natrium-dependent co-transporters or G-protein-
coupled bile acid receptor 1 (Kim et al. 2002, Perides et al. 2010), and from 
serum or interstitium via bicarbonate-dependent bile acid exchangers on the 
basolateral acinar cell surface (Kim et al. 2002).  
2.2.2 INTRA-ACINAR EVENTS 
 
Pathologic calcium signaling 
Despite the initiating factor, an excessive rise in the cytoplasmic calcium 
concentration has been hypothesized to function as a trigger for the initiation 
of AP. While physiologic calcium spikes that regulate normal acinar cell 
functions are transient, pathologic sustained calcium release occurs during the 
early phase of AP. Sustained intracellular calcium release originates from the 
apical endoplasmic reticulum stores and acidic intracellular calcium stores, 
resulting in their sustained calcium depletion, which is followed by an 
excessive calcium entry from the interstitial fluid via the activation of the 
plasma membrane store operated calcium entry channel (Parekh and Putney 
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2005, Gukovskaya et al. 2016). Calcium overload leads to endocytic vacuole 
formation, adenosine triphosphate depletion, oxidative stress, and 
mitochondrial dysfunction, which further mediate acinar cell death pathways 
(Booth et al. 2011, Voronina et al. 2015, Mukherjee et al. 2016).   
 
Premature trypsinogen activation  
The traditional theory of the pathogenesis of AP is based on autodigestion 
caused by premature activation of trypsinogen to trypsin within the acinar cell 
(so-called trypsin-centered theory, first proposed by Chiari in 1896). In a 
normal physiologic condition, trypsinogen and other pancreatic proteases are 
produced and secreted as inactive zymogen granules that are only activated 
after they reach the duodenum. Digestive enzyme secretion is mediated by 
transient calcium spikes localized to the apical granular area. In AP apical 
exocytosis of zymogen granules is inhibited. Due to their altered intracellular 
trafficking, zymogens and lysosomal hydrolases, such as cathepsins, become 
co-localized into intra-acinar cell cytoplasmic vacuoles via a process called 
chrinophagy (Steer and Meldolesi 1987). Within these vacuoles, the lysosomal 
hydrolases activate trypsinogen, and trypsin further activates the other 
zymogens. The organelles containing activated zymogens become fragile and 
release their contents inside the acinar cell. Consequently, acinar cell 
injury/death pathways are activated (van Acker et al. 2006).  
 
Local activation of NF-ĸB 
Recent data suggest that intra-acinar NF-ĸB activation occurs very early in 
experimental AP independently of, yet concurrently with, trypsinogen 
activation (Gukovsky et al. 1998, Hietaranta et al. 2001). The NF-ĸB pathway 
is one of the key inflammatory pathways mediating the expression of a large 
number of genes and subsequent pro- and anti-inflammatory cytokine 
production, and its activation increases the severity of experimental AP 
(Rakonczay et al. 2008, Huang et al. 2013).  
2.2.3 INNATE AND ADAPTIVE IMMUNE RESPONSES 
  
Inflammation, a tightly regulated complex network of different humoral and 
cellular responses, is a protective response to harmful stimuli such as 
microbial pathogens or damaged cells. While its ultimate aim is to eliminate 
the initial cause of cell injury, clear out damaged cells, and initiate tissue 
repair, an excessive and uncontrolled inflammatory response (such as in SAP 
or sepsis) is detrimental to the host, as is also insufficient inflammation. The 
immune system may be divided into innate and adaptive responses that work 
in close collaboration. The main components and functions of the innate and 
adaptive immune systems are presented in Table 1.  
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Table 1. Comparison between innate and adaptive immune responses 
 Innate immune response Adaptive immune response 
Components Physical and chemical barriers 
Granulocytes 
Monocytes/macrophages 
Dendritic cells 
Natural killer cells 
Mast cells 
Plasma proteins (complement) 
Humoral immunity (B lymphocytes) 
Cell-mediated immunity (T 
lymphocytes, natural killer cells) 
Age Fully mature at birth Immature at birth 
Response Immediate response Delayed response over 1-2 weeks 
Actions Barrier functions 
Phagocytosis 
Cytotoxic effects  
Activation of inflammatory response 
Production of inflammatory 
mediators 
Activation of adaptive immune 
system (e.g. antigen presentation) 
Specific antibody production  
Activation of phagocytic cells 
Cytokine production 
Cytotoxic effects 
Controlling immune tolerance 
Production of memory cells 
Specificity General, recognizes PAMPs and 
DAMPs via fixed set of receptors 
Recognizes highly specific antigens 
through specific receptors 
Memory Short-lived Long-term (development of memory 
cells) 
Abbreviations: DAMP, Damage-associated molecular pattern; PAMP, Pathogen-associated 
molecular pattern. 
 
While the innate immune system provides immediate but unspecific defense, 
the adaptive immune system is more sophisticated by offering targeted 
defense, but it reacts with a delay of some 1-2 weeks. The innate immune 
system recognizes conservative structures of foreign danger molecules 
through pattern recognition receptors (PRRs). Such danger molecules 
comprise pathogen-associated molecular patterns (PAMPs), which are derived 
from invading pathogens, and DAMPs, which are induced as a result of 
endogenous stress (Shi et al. 2003). Of the PRRs, the Toll-like receptors 
(TLRs) are the best-characterized family. Activation of TLRs activates 
downstream signaling pathways, such as NF-ĸB, MAPK, and STATs, leading 
to increased transcription of inflammatory genes and subsequent production 
of proinflammatory cytokines such as tumor necrosis factor (TNF) and 
interleukin (IL) 1 (Chen and Nunez 2010).  
The adaptive immune system recognizes highly specific antigens, 
presented by specialized antigen-presenting cells, through specific receptors. 
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When activated, the cells of the adaptive immune system, namely T and B cells, 
provide targeted responses against the invading pathogen. 
Traditionally, only adaptive immunity has been thought to be responsible 
for building immunological memory through production of memory cells 
during primary response. As a result, the immune system responds more 
rapidly and effectively to pathogens that have been encountered previously. 
However, also the cells of the innate immune system, such as macrophages, 
monocytes, and natural killer cells, show enhanced responsiveness when they 
re-encounter pathogens. This phenomenon is called “trained immunity” or 
“innate immune memory” that is shorter lived and a result of epigenetic 
reprogramming, i.e. it does not involve permanent genetic changes (Netea et 
al. 2016).    
2.2.3.1 Inflammatory cells 
Humoral inflammatory mediators activate and recruit circulating 
inflammatory cells to the site of inflammation. Leukocyte adhesion to the 
endothelium is essential for the development of an appropriate immune 
response. Neutrophils are the first recruited cells, following infiltrating 
monocytes/macrophages and lymphocytes.  
 
Neutrophils  
Recruitment of neutrophils to the inflammatory site is one of the hallmarks of 
the early phase of inflammation. Neutrophils are produced in the bone 
marrow, and in the steady state they circulate in the blood for a few hours, 
after which they undergo apoptosis. Apoptotic neutrophils are engulfed by 
macrophages and dendritic cells, which further regulates the neutrophil 
production in the bone marrow. Upon inflammatory reaction, granulocyte 
colony-stimulating factor (G-CSF) is essential for enhancing neutrophil 
production to meet the increased need, and neutrophils expand their life span 
in the circulation by several days (Lieschke et al. 1994, Borregaard 2010). To 
arrive at the site of inflammation, the neutrophils must cross the vascular wall.  
The vascular endothelium is activated by proinflammatory cytokines, such 
as TNF-α, IL-1β, and IL-17, which results in enhanced expression of P- and L-
selectin, integrins such as CD11b/CD18, and the immunoglobulin superfamily 
proteins intercellular adhesion molecule 1 and vascular cell adhesion molecule 
1 (Repo and Harlan 1999). As a result, stepwise adhesion (initial attachment, 
rolling, firm adhesion) of neutrophils to the vascular walls and their 
transendothelial migration occurs (Repo and Harlan 1999, Borregaard 2010). 
The activated endothelial wall secretes also e.g. IL-8, which activates 
additional neutrophils (Borregaard 2010). The adhesion molecules L-selectin, 
CD11b, and CD18 serve as neutrophil activation markers.  
Activated tissue neutrophils contribute to further tissue injury by 
generation of oxygen free radicals, protease degranulation, promotion of 
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endothelial dysfunction, and recruitment of additional leukocytes (Liu et al. 
2014). Negative feedback exists at several stages to control neutrophil influx 
to prevent neutrophil-mediated tissue damage, but under excessive neutrophil 
infiltration these mechanisms may fail (Borregaard 2010). Neutrophils play a 
central role in the development of local as well as systemic complications in 
SAP. In part through the production of oxygen free radicals, infiltrating 
neutrophils stimulate both acinar cell damage and pancreatitis-associated 
lung injury (Frossard et al. 1999, Gukovskaya et al. 2002). Indeed, depletion 
of neutrophils has been shown to attenuate experimental AP (Sandoval et al. 
1996, Gukovskaya et al. 2002). 
Neutrophils may contribute to host response also by expelling neutrophil 
extracellular traps (NETs) that can trap and kill invading bacteria 
(Brinkmann et al. 2004). NETs consist of smooth “threads”, composed of 
neutrophil deoxyribonucleic acid (DNA) and histones, covered with globular 
domains that contain granular proteins (Brinkmann et al. 2004). In vitro the 
NETs are expelled during specific neutrophilic cell death type, namely 
NETosis (Brinkmann and Zychlinsky 2007), but there is also data indicating 
that expelling NETs does not necessarily result in cell death (Yipp et al. 2012). 
The NETs are formed as a response to a variety of proinflammatory stimuli, 
such as TNF-α, IL-8, and lipopolysaccharide (LPS), and prevention of 
bacterial dissemination may be their main antibacterial function (Remijsen et 
al. 2011, Leliefeld et al. 2016).  
Excessive release of NETs causes cytotoxic effects, and growing evidence 
suggests that NETs have tissue-damaging properties (Liu et al. 2014, Leliefeld 
et al. 2016). Recently, NETs have been detected in the inflamed murine 
pancreas, and their possible role in recruitment of neutrophils and 
trypsinogen activation during experimental AP has been propounded 
(Korhonen et al. 2015, Merza et al. 2015). In another experimental study, 
neutrophils were observed to enter the lumen of biliopancreatic ducts under 
inflammatory conditions and form aggregated NETs, which then hampered 
secretory flow, thus driving focal pancreatitis (Leppkes et al. 2016).  
 
Monocytes/Macrophages  
Resident tissue macrophages are present virtually in all cell types, where they 
engulf dead cells, debris, and foreign material and orchestrate the 
inflammatory process. During inflammatory reaction circulating monocytes of 
bone marrow origin are recruited to the tissues and differentiate into 
macrophages (Varol et al. 2015). The migration through the endothelial wall is 
mediated by several adhesion molecules and is similar to that of neutrophils 
(Repo and Harlan 1999). Macrophages are the main source of pro- and anti-
inflammatory cytokines, chemokines, and lipid mediators, and they recruit 
additional inflammatory cells to the site of inflammation (Xue et al. 2014). 
During inflammation macrophages are vivid phagocytes, and they also 
function as antigen-presenting cells, thus activating T cells of the adaptive 
immune system.  
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Lymphocytes  
Lymphocytes include T and B cells and natural killer cells. While T and B cells 
are the primary cells of the adaptive immune system, natural killer cells 
participate in both innate and adaptive immune responses. Most of the 
circulating lymphocytes are T cells.  
T cells mature in the thymus mainly to CD4 expressing T helper (Th) cells 
or CD8 expressing cytotoxic T cells. These antigen-naïve T cells circulate in the 
body and become activated in the lymph node during antigen presentation. T 
cell receptors of CD4+ cells engage peptides bearing major histocompatibility 
complex class II, such as human leukocyte antigen –antigen D related (HLA-
DR), whereas CD8+ cells engage peptides bearing major histocompatibility 
complex class I. Depending on the type of antigen-presenting cell and the 
cytokine milieu at the site of antigen encounter, naïve CD4+ T cells 
differentiate into distinct populations (Th1, Th2, Th17, or Th9) that secrete a 
unique mixture of cytokines, although overlapping cytokine expression 
profiles are possible (Bonilla and Oettgen 2010).  
Activated T cells migrate to the site of infection, where CD4+ T cells 
enhance both B and T cell response and CD8+ T cells eliminate pathogens by 
killing infected target cells (Bonilla and Oettgen 2010). During AP, CD4+ T 
cells have an important role in macrophage activation and they have also direct 
cytotoxicity effects on acinar cells (Demols et al. 2000). A small part of the 
circulating T cells is called regulatory T cells, which are actively involved in 
maintaining immune tolerance (Chatila 2005).  
B cells reach maturity already within the bone marrow. After antigen 
encounter in lymphoid tissue, such as the spleen or lymph node, activated B 
cells develop into mature plasma cells and secrete immunoglobulins, the 
antigen-specific antibodies responsible for eliminating extracellular 
microorganisms (Delves and Roitt 2000).  
Natural killer cells are a group of cytolytic lymphocytes that destroy 
infected and malignant cells. They also function as regulatory cells interacting 
with dendritic cells, macrophages, T cells, and endothelial cells (Delves and 
Roitt 2000).   
 
Other cells 
Dendritic cells are the most powerful antigen-presenting cells in the 
immune system, and they drive both innate and adaptive immune systems. 
Immature dendritic cells circulate in the body and recognize DAMPs through 
PRRs on their cell surface. After the binding to the receptor, immature 
dendritic cells become activated and migrate to nearby lymph nodes, where 
they process the antigen and present it to T cells. Dendritic cells have a crucial 
role in inflammation since they are the most powerful antigen-presenting cells 
and instructors of T cell response. A marked increase in the numbers of 
intrapancreatic dendritic cells has been shown in experimental AP, where they 
seem to have a dual role. They are capable of releasing proinflammatory 
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cytokines, but also protect the pancreas from severe injury. However, these 
mechanisms are not fully understood (Bedrosian et al. 2011).  
Mast cells are a type of granulocyte found preferentially in the skin, 
mucosal surfaces, and around blood vessels. Upon activation, they proliferate 
at the site of inflammation and release vasoactive agents such as histamine, 
various inflammatory mediators including several leukocyte 
chemoattractants, and proteolytic enzymes from their intracellular granules. 
Mast cells are typically involved in allergic reaction and anaphylaxis. They 
have also capacity to phagocytize and kill bacteria, and they appear critical for 
the early neutrophil response to bacterial infection by secreting 
chemoattractants. Mast cells also contribute to adaptive immune responses 
through antigen presentation and release of immunoregulatory cytokines, 
thus influencing the development of specific T and B cell responses (Abraham 
and Arock 1998). During experimental AP activated mast cells have been 
shown to be involved in the development of endothelial barrier dysfunction in 
both the pancreas and extrapancreatic tissues, particularly in the lungs and 
colon, and contribute to the development of organ dysfunction (Dib et al. 
2002). 
 Apart from controlling thrombosis and hemostasis, platelets are also 
involved in proinflammatory activities. They are activated by various 
inflammatory mediators, are a source of numerous chemokines, express 
various adhesion molecules, and release factors that can help to kill bacteria 
and infected cells (Semple and Freedman 2010). Platelets can also induce NET 
formation during bacterial infection (Clark et al. 2007), but not necessarily in 
sterile inflammation (Slaba et al. 2015).   
2.2.3.2 Inflammatory mediators 
 
Cytokines  
Cytokines include interleukins, chemokines, interferons, colony-stimulating 
factors, and many growth factors. They are pleiotropic low-molecular-weight 
proteins that regulate host responses to infection, immune responses, 
inflammation, and trauma through cell-to-cell interactions, and are active in 
extremely small concentrations. There is also immense redundancy among 
cytokines, with many cytokines sharing similar biologic effects, and therefore, 
the traditional classification of cytokines as either proinflammatory or anti-
inflammatory is somewhat artificial; many of the cytokines may have both 
effects depending e.g. on the time course of the immune response (Cavaillon 
2001). Cytokines bind to specific cell surface receptors, and subsequent events 
of intracellular signaling then alter cell functions (Norman 1998, Dinarello 
2000, Scheller et al. 2011). The systemic signs and symptoms of excess 
inflammatory cytokines are due to elevated cytokine levels, but also the 
receptors on potential target cells and the machinery to export the active 
protein are upregulated (Norman 1998, de Beaux et al. 1996).   
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 TNF-α is a crucial first-line mediator of inflammation. The effects of TNF-
α are transmitted through two different cell surface receptors, TNF-α receptor 
1 and TNF-α receptor 2, which downregulate signaling cascades involving 
protein kinases and transcriptional factors, resulting in the induction of other 
cytokines (such as IL-6 and IL-8) and cell adhesion molecules (Malleo et al. 
2007).  TNF-α also intensifies oxidative stress and causes damage to the 
capillary endothelial cells and postcapillary venules that become procoagulant 
and proadhesive. Thus, TNF-α recruits and further activates neutrophils, 
resulting in further superoxide production and cell damage (Malleo et al. 
2007). Finally, TNF-α orchestrates the spreading of local inflammatory 
reaction to the systemic illness.   
 IL-6 is elevated in most, if not all, inflammatory states. IL-6 induces all 
major acute-phase proteins in the liver, including C-reactive protein (CRP) 
(Castell et al. 1989). It is crucial to the resolution of acute neutrophil 
infiltration by inducing neutrophil apoptosis and inducing a switch from 
neutrophil to monocyte recruitment (Kaplanski et al. 2003, Chen et al. 2006, 
Scheller et al. 2011). IL-6 also affects many T cell activities; it induces T cell 
recruitment, controls the proliferation and survival of Th1 and Th2 lineage 
cells, is a key driver of the Th17 lineage, and can inhibit regulatory T cell 
functions (Hunter and Jones 2015). IL-6 stimulates target cells via either the 
classic signaling route, which mediates regenerative or anti-inflammatory 
activities, or through trans-signaling, which mediates proinflammatory 
responses (Scheller et al. 2011).  
 IL-8 is a chemokine that induces chemotaxis of leukocyte subsets (Adams 
and Lloyd 1997). It is primarily secreted by mononuclear phagocytes, but also 
by other cells, particularly endothelial cells, upon exposure to 
proinflammatory stimuli. IL-8 triggers neutrophil adhesion to the 
endothelium, directs migration into the tissue along the IL-8 gradient 
(recruitment of cells occurs towards an area of increased IL-8 concentration), 
and activates neutrophil effector mechanisms in the tissue (Adams and Lloyd 
1997, Remick 2005). It is noteworthy that the biological activity of IL-8 is 
related more to the gradient of IL-8 rather than to the absolute IL-8 level. IL-
8 may exert also anti-inflammatory effects if the gradient is in the wrong 
direction (away from the site of inflammation). Its unique feature in contrast 
to most inflammatory cytokines is that it may be produced early in the 
inflammatory response, but will persist for days or even weeks (Remick 2005).   
Hepatocyte growth factor (HGF), originally identified as a mitogenic 
protein for rat hepatocytes (Nakamura et al. 1984, Russell et al. 1984), has 
multiple effects on tissue regeneration and is associated with proliferation, 
migration, and 3-D morphogenesis. The receptor for HGF is a Met tyrosine 
kinase.  In mature tissues, HGF regulates cell survival by suppressing 
apoptosis, although it may also promote apoptosis of cells responsible for 
tissue fibrosis and induces expression of proteases (such as matrix 
metalloproteinases) involved in breakdown of the extracellular matrix scaffold 
(Nakamura et al. 2011). Recent studies have shown that HGF also regulates 
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the function of immune cells such as dendritic cells and a subset of regulatory 
T cells (Okunishi et al. 2005, Benkhoucha et al. 2010). Overall, the HGF-Met 
pathway prevents inflammation and fibrotic change in many tissues, and its 
tissue protective and/or regenerative effect has been demonstrated in several 
tissues, including kidney, lung, and gastrointestinal tissue. Clinical trials using 
recombinant human HGF protein or HGF genes are underway for numerous 
disease models in various tissues (Nakamura et al. 2011).   
 G-CSF is a crucial regulator of neutrophil production under both basal 
and stress conditions (Lieschke et al. 1994), and it also prolongs the survival 
of neutrophils and their precursors. For mature neutrophils, G-CSF enhances 
key functions such as superoxide production, phagocytosis, and bacteriocidal 
killing (Roberts 2005). Apart from neutrophils, G-CSF also influences 
dendritic and T cell function. In routine hospital protocol, G-CSF is used to 
increase the production of neutrophils in patients with chemotherapy-induced 
neutropenia (Roberts 2005).  
  
Exogenic activators 
LPS is a crucial component of an outer membrane that surrounds Gram-
negative bacteria, such as Escherichia coli (E. coli), and mutants that are 
unable to form LPS are not viable. The outer membrane protects bacteria from 
toxic compounds (such as antibiotics) and mediates the physiological and 
pathophysiological interaction of bacteria with the host organism (Rietschel et 
al. 1994). Although most of the bacterial products can induce inflammation, 
LPS is one of the most powerful ones.  The early step in cell activation by LPS 
is mediated by the LPS-binding protein to form LPS/LPS-binding protein 
complexes (Schumann et al. 1990), which are then recognized by PRRs such 
as CD14 (Wright et al. 1990) and TLR4 (Poltorak et al. 1998). Since CD14 lacks 
an intracellular domain, TLR4 is required for transmitting LPS signal from 
membrane-bound CD14 to the cytoplasm. Via soluble CD14 receptor, LPS may 
also activate CD14-negative cells such as endothelial cells (Heumann and 
Roger 2002).   
E. coli is a Gram-negative coliform bacterium that belongs to the gut 
normal flora. It was first discovered by pediatrician Theodor Escherich (1885). 
There are several E. coli strains, some of which are pathogenic and some not. 
Pathogenic E. coli strains are responsible for infections of the gut, urinary 
tract, and lungs, among others.  The virulence factors of different E. coli strains 
contain adhesins, iron acquisition systems, polysaccharide coats, and some 
have the ability to secrete toxins (Sannes et al. 2004, Vila et al. 2016). The 
complete genome of E. coli K-12 laboratory strain was published in 1997 
(Blattner et al. 1997), and several hundred complete genomic sequences of E. 
coli are currently available.   
Phorbol-12-myristate-13-acetate (PMA) is a phorbol ester 
commonly used in research to activate certain types of protein kinase C, and 
subsequently, MAP kinase pathways (Blumberg 1988, Seger and Krebs 1995).  
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2.2.3.3 Signaling pathways 
Cell signaling is a process through which cells coordinate their actions 
according to the signals they recognize via cell surface receptors. Following the 
activation of a receptor, a cascade of events transports the signal ultimately to 
the nucleus, leading to an altered gene and protein synthesis with numerous 
impacts. The major inflammation-associated leukocyte signaling pathways 
include NF-ĸB, ERK1/2 MAPK, and STATs. 
 
 NF-ĸB 
 
NF-ĸB belongs to the Rel/NF-ĸB family of transcription factors, including 
RelA, c-Rel, RelB, NF-ĸB1 (p50 and its precursor protein p105), and NF-ĸB2 
(p52 and its precursor protein p100). They normally reside in the cytoplasm, 
where they are kept inactive by inhibitors of ĸB (IĸB), the most important of 
which are IĸBα and IĸBβ. Two major signaling pathways, the canonical and 
alternative NF-ĸB pathways, exist (Rakonczay et al. 2008).  
In the classical/canonical pathway (Figure 1), proinflammatory cytokines 
and PAMPs activate different receptors such as PRRs (including all TLRs), 
antigen receptors, and receptors for members of the TNF and IL-1 cytokine 
families. As a result, IĸB kinase complex is activated, and IĸBs are rapidly 
phosphorylated at specific serine residues. This allows NF-ĸB to translocate to 
the nucleus, where it binds DNA and activates gene transcription, such as TNF 
and IL-1β, which amplify further NF-ĸB activation (Bonizzi and Karin 2004, 
Rakonczay et al. 2008). The classical pathway is crucial in the innate immune 
responses. It encodes chemokines, cytokines, and adhesion molecules, such as 
intercellular adhesion molecule 1 and vascular cell adhesion molecule 1, which 
recruit inflammatory cells to the site of inflammation.  
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 NF-ĸB signaling (classical pathway). Normally, NF-ĸB is inactive and resides in the 
cytoplasm. When cells are stimulated by an activating signal, such as TNF-α, IĸB 
kinase rapidly phosphorylates inhibitors of ĸB and targets them for proteasomal 
degradation. When IĸB degrades, nuclear translocation signals of NF-ĸB are 
unmasked, and NF-ĸB is able to translocate into the nucleus, where it binds to its 
cognate DNA sequence and induces the transcription of its target genes. 
Abbreviations: IĸBα, Inhibitor of ĸB; TNF, Tumor necrosis factor; TNFR, Tumor 
necrosis factor receptor 
NF-ĸB activation can also occur independently of IĸB phosphorylation or 
degradation; this is known as the alternative or non-canonical pathway. 
During the inflammatory response the alternative NF-ĸB pathway is suggested 
to have a role in lymphoid organ development and adaptive immunity 
(Vallabhapurapu and Karin 2009). 
 
 MAPK 
 
The MAPK signaling pathway promotes cellular processes, such as 
proliferation, differentiation, and development, and dysregulation of this 
pathway is common in cancer. ERK1 and ERK2, collectively called ERK1/2 due 
to their high degree of similarity, are among the 14 MAPKs described in 
mammals. Each of these signaling cascades consists of several tiers of different 
protein kinases that sequentially activate each other by phosphorylation 
allowing for rapid and regulated transmission of the original initiating signal. 
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The core cascade is usually composed of three tiers: mitogen-activated protein 
kinase kinase kinase (MAP3K), MAP2K, and MAPK (Rubinfeld and Seger 
2005). The upstream activation of MAP3Ks is complex, and different MAP3Ks 
can have varied activation mechanisms.  For example, tumor progression locus 
2 is a MAP3K for the ERK1/2 pathway (Arthur and Ley 2013). During the 
innate immune response MAPK activation has been mostly studied in 
macrophages and dendritic cells in the context of TLR agonists (Figure 2). 
 
 
 ERK1/2 signaling following activation of Toll-like receptor. Following activation 
of Toll-like receptor (TLR), myeloid differentiation primary-response protein 88 
(MYD88) is recruited to the intracellular domain of the receptor, thus initiating a 
cascade of events that eventually leads to the activation of tumor progression locus 
2 (TLP2). Active TLP2 phosphorylates MAPK kinase 1 and 2 (MKK1/2), which 
subsequently leads to the phosphorylation of ERK1/2, further phosphorylating 
transcription factors that control gene expression in the nucleus. Abbreviations:  
DAMP, Damage-associated molecular pattern; MAPK, Mitogen-activated protein 
kinase; MAP2K, Mitogen-activated protein kinase kinase; MAP3K, Mitogen-activated 
protein kinase kinase kinase; MKK1/2; Mitogen-activated protein kinase 1 and 2; 
MYD88, Myeloid differentiation primary-response protein 88; PAMP, Pattern-
associated molecular pattern; TLP2, Tumor progression locus 2; TLR, Toll-like 
receptor. 
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 STATs 
 
The Janus kinase (JAK)-STAT signaling pathway is employed in the signaling 
of many cytokines. Cytokine receptors lack, in general, intrinsic tyrosine 
kinase activity, therefore requiring an association with receptor-associated 
kinases (i.e. JAKs) in order to propagate a phosphorylation cascade. Cytokine 
receptor phosphorylation allows binding of STATs, after which 
phosphorylation of STATs by JAKs ensues. Phosphorylation leads to STAT 
homo- and heterodimerization. STAT dimers are rapidly transported from the 
cytoplasm to the nucleus and bind to DNA in order to alter transcription 
(Aaronson and Horvath 2002, Scott et al. 2002).   
There are seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B 
and STAT6) and four JAKs (JAK1, JAK2, JAK3, and TYK2) in mammals. 
STAT1, STAT2, STAT3, STAT5, and STAT6 are present in various tissues. In 
an experimental mouse model of AP, these STATs were also present in 
pancreatic tissue, where acinar cells were the main source of STAT1, STAT2, 
STAT3, and STAT5, and STAT6 originated from non-acinar cells (Gallmeier et 
al. 2005). Regulation of JAK/STAT pathways is crucial in immune response, 
and the pathway is regulated by a number of intrinsic and environmental 
stimuli. Negative regulation pathways include receptor degradation and 
dephosphorylation of activated STAT dimers and suppressors of cytokine 
signaling proteins that inactivate JAKs (Aaronson and Horvath 2002, Scott et 
al. 2002).   
STAT1 forms part of a major signaling pathway for interferon gamma, a 
proinflammatory cytokine that increases Th1 differentiation and cell-
mediated immune responses and is crucial for the activation of macrophages 
and monocytes (Kim and Maniatis 1996, Scott et al. 2002). STAT1-deficient 
mice have been shown to possess a complete lack of responsiveness to 
interferon gamma and to be highly sensitive to infection by microbial 
pathogens and viruses (Meraz et al. 1996).   
 The STAT3 pathway (Figure 3) was first discovered as a mediator of acute-
phase response in the liver induced by IL-6, IL-1β, and TNF-α (Akira et al. 
1994). Later, it has been shown to be activated also by various other cytokines 
such as G-CSF, epidermal growth factor, leptin, and IL-10 (Takeda et al. 1999). 
STAT3-deficient knock-out mice die early in the fetal stage, but tissue-specific 
targeting of STAT3 causes only distinctive abnormalities. For example, STAT3 
deficiency in T cells impaired IL-2 and IL-6-induced T cell proliferation 
(Takeda et al. 1998), and in macrophages and neutrophils STAT3 deficiency 
led to impaired IL-10 responsiveness (Matsukawa et al. 2003).  
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 STAT3 signaling. STAT3 signaling pathway is activated when a ligand, such as IL-
6, binds to its receptor. This leads to the recruitment and activation of the JAK family 
of proteins, which in turn recruits and phosphorylates latent STAT3 in the cytoplasm. 
STAT3 can also be directly phosphorylated by non-tyrosine kinase receptors (Src). 
Phosphorylated STAT3 homodimerizes and translocates to the nucleus, where it 
regulates gene expression. Abbreviations: IL, Interleukin; IL6R, IL-6 receptor; JAK, 
Janus kinase; Src, Src-kinase; STAT, Signal transducer and activator of transcription. 
2.2.4 ACINAR CELL DEATH  
  
Along with the host’s inflammatory reaction, cell death modality is one of the 
key factors determining the course and prognosis of AP.   
2.2.4.1 Apoptosis  
 
Apoptosis is a tightly regulated form of cell death, morphologically 
characterized by cell shrinkage, integral cell membrane, nuclear condensation, 
and formation of apoptotic bodies (Kerr et al. 1972). Extracellular or 
intracellular stress signals initiate apoptosis, mainly through caspase-
dependent pathways (Thornberry and Lazebnik 1998, Galluzzi et al. 2012). 
Apoptotic bodies are recognized by phagocytes and engulfed before they leak 
their contents into the extracellular space. (Taylor et al. 2008). 
Developmentally programmed apoptotic cell death is crucial for life and is 
considered immunologically silent. However, pathological apoptotic cell death 
indicates tissue injury and should be detected by the immune system. Indeed, 
recent studies suggest that in certain situations apoptotic cells can be 
proinflammatory through the release of a limited amount of DAMPs, or 
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apoptotic cells themselves can produce cytokines and chemokines, thus 
actively engaging the immune system (Cullen et al. 2013, Kearney et al. 2013, 
Wickman et al. 2013).  On the other hand, apoptotic cell death has been shown 
to suppress inflammation though cell surface changes, which induce the 
generation of anti-inflammatory mediators (Voll et al. 1997). In experimental 
AP studies, apoptosis has been demonstrated to be the major form of cell death 
in mild AP (Kaiser et al. 1995).  
2.2.4.2 Regulated necrosis 
 
Necrotic cells exhibit translucent cytoplasm, swelling of organelles, and 
disruption of the plasma membrane with the release of endogenous molecules 
(i.e. DAMPS) that directly trigger a proinflammatory response (Kaczmarek et 
al. 2013). In the past, necrosis was thought to be an unscheduled and 
unregulated form of cell death induced by overwhelming external stress, but 
growing evidence indicates that, at least in part, necrotic cell death is finely 
regulated by a set of intracellular signal transduction pathways (Golstein and 
Kroemer 2007). Regulated necrosis can be further characterized with regard 
to its dependence on specific signaling modules into necroptosis, parthanatos, 
ferroptosis, oxytosis, mitochondrial permeability transition-dependent 
necrosis, pyroptosis, and pyronecrosis, and cell death is associated with the 
release of (neutrophil) extracellular traps, which is described as NETosis 
(ETosis) (Pasparakis and Vandenabeele 2015).  
The best-characterized form of regulated cell necrosis, which has been 
detected in experimental AP, is necroptosis (Zhang et al. 2009, Sun et al. 
2012, Wu et al. 2013, Ma et al. 2015, Louhimo et al. 2016). By definition, 
necroptosis can be further characterized with regard to its dependence on 
specific signaling modules (receptor-interacting protein 1 or receptor-
interacting protein 3 dependent) (Galluzzi et al. 2012). Morphologically, 
necroptosis is similar to necrosis, and necroptosis is also thought to result in 
the release of DAMPs into the extracellular space. For this reason, necroptosis 
is currently considered to be a highly inflammatory mode of cell death 
(Davidovich et al. 2014). Since several of the upstream signaling elements of 
apoptosis and necroptosis are shared, overlapping mechanisms between 
different cell death types exist (Linkermann and Green 2014). Recent 
preliminary studies have also shown that inhibition of necroptosis would be 
beneficial in experimental AP (Zhang et al. 2009, Sun et al. 2012, Wu et al. 
2013, Ma et al. 2015), even after the onset of AP (Louhimo et al. 2016). Also 
blocking necroptosis in TNF-induced systemic inflammatory response 
syndrome (SIRS) protected mice against lethal SIRS (Duprez et al. 2011).  
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2.2.4.3 Nucleosomes   
 
The nucleosome is an example of a nuclear DAMP. Besides nucleosomes, other 
DAMPs include nucleosome components (histones and DNA), high-mobility 
group box 1 (HMGB1), s100 proteins, heat shock proteins, hyaluronic acid, 
uric acid, adenosine triphosphate, and ribonucleic acid (Tang et al. 2012, Kang 
et al. 2014a). The nucleosome is a basic unit of nuclear chromatin, and it is 
composed of a central core protein formed by an octamer of the double-
represented histone and 147 pairs of double-stranded DNA. Single 
nucleosomes are connected by so-called linker DNA, and a further histone is 
located at these linking sites outside the nucleosomes, stabilizing the chain in 
its tertiary structure. The nucleosome structural organization plays an 
essential role in regulating gene transcription and facilitates efficient higher-
order chromatin compaction (Oudet et al. 1975, Luger 2003).  
Upon physiological cellular damage, nucleosomes are released into the 
extracellular space, where they are engulfed by macrophages and neighboring 
cells (Bell and Morrison 1991). Small levels of circulating nucleosomes can be 
found in healthy persons, but enhanced cell death (apoptosis, regulated 
necrosis, NETosis) leads to impaired elimination systems, and thus, higher 
circulating nucleosome levels are found in various pathologic conditions 
(Holdenrieder and Stieber 2009). Elevated nucleosome levels have also been 
found in experimental AP (Kang et al. 2014b). Moreover, the nucleosome 
components, DNA and histone, serve as DAMPs; elevated levels of circulating 
DNA have been found to be associated with the severity of human AP (Gornik 
et al. 2009, Kocsis et al. 2009, Gornik et al. 2011), and elevated histone levels 
with the severity of experimental AP (Ou et al. 2015).   
 The origin of circulating nucleosomes, but also circulating histones and 
cell-free DNA, seems to be diverse, including dying non-myeloid cells through 
apoptotic and necrotic cell death, but also dying activated neutrophils (a cell 
death form called “NETosis”) (reviewed in Marsman et al. 2016). Of note, 
nucleosomes, histones, and cell-free DNA seem to have differences in 
immunostimulation e.g. the cytotoxic effects ascribed to histones do not 
appear to apply to nucleosomes (Gauthier et al. 1996, Xu et al. 2009, Marsman 
et al. 2016).  Nucleosomes contribute to immune reaction by, for instance, 
inducing neutrophil and dendritic cell activation and subsequent 
proinflammatory cytokine production (Decker et al. 2005, Lindau et al. 2011,). 
Nucleosomes may also form complexes with another potent nuclear DAMP, 
namely HMGB1, which in turn activates macrophages to produce cytokines 
(Urbonaviciute et al. 2008). Cell-surface proteoglycans have been found to be 
involved in the binding of nucleosomes to cell surfaces (Watson et al. 1999). 
In addition, the existence of a nucleosome-specific receptor has been 
proposed, but has not yet been identified (Marsman et al. 2016).    
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2.2.5 LOCAL AND SYSTEMIC INFLAMMATORY RESPONSE  
 
Proinflammatory response 
The severity of AP attack is determined by the extent of inflammatory reaction 
and the host’s response to it, not by the amount of pancreatic damage. 
According to the current theory, local activation of NF-ĸB in acinar cells, and 
acinar cell death caused by premature trypsinogen activation are two early 
parallel events after the onset of AP that induce local inflammation in the 
pancreas (Gukovsky et al. 1998, Rakonczay et al. 2008). The NF-ĸB signaling 
pathway mediates the production of proinflammatory cytokines, such as TNF-
α and IL-1β, which then activate other signaling pathways, such as STAT1, 
STAT3, and ERK1/2 MAPK, in the pancreas (Dabrowski et al. 1996, Gallmeier 
et al. 2005). Acinar cell death leads to the release of immunogenic DAMPs 
outside the acinar cells that activate downstream signaling pathways, resulting 
in increased transcription of inflammatory genes and subsequent production 
of proinflammatory cytokines (Chen and Nunez 2010).  
Release of proinflammatory cytokines and chemokines activates the 
endothelium, and circulating inflammatory cells, first neutrophils and then 
monocytes/macrophages and lymphocytes, are recruited into the pancreas. 
Sequestered inflammatory cells, especially macrophages, in turn produce 
more cytokines and recruit additional leukocytes into the pancreas, which is 
later followed by leukocyte recruitment into distant organs such as the lung 
(McKay et al. 1996). Proinflammatory cytokines also activate tissue resident 
macrophages in remote organs (such as the peritoneum, liver, and lungs), 
which then produce proinflammatory cytokines, thus contributing to the 
systemic progression of AP (Shrivastava and Bhatia 2010). The activated 
immune system tries to resolve the local inflammation, generally succeeding, 
but if it fails AP may rapidly progress to systemic illness.  
In SAP, the severity of systemic inflammatory response is comparable to 
that seen in bacterial sepsis, with similar clinical symptoms and pattern of 
released inflammatory mediators (Deitch 1992, Wilson et al. 1998). The 
vicious circle that promotes the amplification of a local response into a 
systemic response (Figure 4) involves the extrapancreatic activation of NF-ĸB 
and other signaling pathways, systemic production of proinflammatory 
cytokines, and excessive neutrophil infiltration in remote organs (Rakonczay 
et al. 2008, Kylänpää et al. 2012). Excessive and uncontrolled neutrophil 
infiltration leads to the accumulation of toxic neutrophil products that induce 
cell death and damage to vascular endothelial cells. Subsequently, endothelial 
permeability is increased, resulting in the accumulation of tissue fluid and 
edema (Kylänpää et al. 2012). Together with microvascular disturbances (e.g. 
vasoconstriction, inadequate perfusion, and increased blood viscosity), 
excessive tissue fluid leads to a lack of oxygen, which results in dysfunction 
and injury of end organs (Menger et al. 2001). Although AP is a sterile disorder 
in the early phase (Beger et al. 1986), increased gut permeability may allow 
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bacterial translocation and endotoxins to the circulation. This may cause 
infection of the necrotic pancreas, and even sepsis (Capurso et al. 2012).  
Along with the activation of inflammatory pathways, the pathogenesis of 
OD consists of major modifications to non-immunological pathways, such as 
those of cardio- vascular, neuronal, autonomic, hormonal, bioenergetic, 
metabolic, and coagulation systems, all of which have prognostic significance 
(Singer et al. 2004).   
 
Compensatory anti-inflammatory response  
Early and simultaneously with the proinflammatory reaction, the anti-
inflammatory response occurs to downregulate the process, which is 
documented by the presence of both pro- and anti-inflammatory cytokines in 
the circulation (Makhija and Kingsnorth 2002, Mentula et al. 2004). This 
phenomenon has been called compensatory anti-inflammatory response 
syndrome (CARS) (Bone 1996). Although the exact mechanisms are still 
poorly understood, the current theory suggests that an excessive anti-
inflammatory response may cause immunosuppression, which, on a cellular 
level, is present already in the early phase of SAP and may be linked to 
increased susceptibility to subsequent infections (Figure 5) (Li et al. 2013, Pan 
et al. 2017).  
The signs of immunological impairment include defects in leukocyte 
signaling (Oiva et al. 2010a, 2010b, 2013), reduced monocyte HLA-DR 
expression (Kylänpää-Bäck et al. 2001a, Mentula et al. 2003), and lymphocyte 
dysfunctions, shown as delayed hypersensitivity in skin testing (Garcia-
Sabrido et al. 1989), reduced circulating lymphocyte count (Christophi et al. 
1985, Takeyama et al. 2000), and impaired activity of CD4+ T cells (Curley et 
al. 1993, Pezzilli et al. 1994). Despite the cellular signs of immunosuppression, 
clinically, a hyperinflammatory phase predominates with shock, fever, and 
hyper-metabolism.  
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 Spreading of local inflammatory reaction into systemic response in acute 
pancreatitis (simplified). Abbreviations: CRP, C-reactive protein; DAMP, Damage-
associated molecular pattern; ERK, Extracellular signal-regulated kinase; HGF, 
Hepatocyte growth factor; HMGB1, High mobility group box 1 protein; IL, Interleukin; 
MCP, Monocyte chemoattractant peptide; MODS, Multiple organ dysfunction 
syndrome; NET, Nuclear extracellular trap; NF-ĸB, Nuclear factor kappa B; PRR, 
Pattern recognition receptor; STAT, Signal transducer and activator of transcription; 
TNF, Tumor necrosis factor.                                                                                                
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 Course of systemic inflammatory reaction (modified from Hotchkiss et al. 2013). 
Abbreviations: CARS, Compensatory anti-inflammatory response; MODS, 
Multiorgan dysfunction syndrome; SIRS, Systemic inflammatory response syndrome. 
2.3 DIAGNOSIS OF ACUTE PANCREATITIS 
2.3.1 MAIN DIAGNOSTIC CRITERIA 
 
The diagnosis of AP requires abdominal pain (acute onset of persistent, severe, 
epigastric pain, often radiating to the back) together with serum lipase or 
amylase activity at least three times greater than the upper limit of normal, 
and/or characteristic findings of AP on abdominal imaging. CECT and 
magnetic resonance imaging (MRI) should be reserved for patients in whom 
the diagnosis is unclear or who fail to improve clinically within the first 48-72 
hours or to evaluate complications (Tenner et al. 2013).  
2.3.2 CLINICAL SYMPTOMS AND SIGNS 
 
The pain usually starts acutely in the upper abdomen and is often described as 
a belt-like pain radiating to the back. The pain worsens rapidly and later 
involves the whole abdomen. The onset of AP is defined as the time of onset of 
abdominal pain, and the time interval between onset of pain and first 
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admission to hospital should be noted (Banks et al. 2013). Other 
gastrointestinal symptoms include nausea and vomiting. Very rare but severe 
symptoms are hematemesis and melena (Lankisch et al. 2015). In the physical 
examination, most patients experience general palpation as painful. Peritoneal 
irritation is often present in a severe attack. Cutaneous signs, i.e. brownish-
green discoloration in the umbilical region (Cullen’s sign), in the flanks (Grey 
Truner’s sign), or in the upper thigh (Fox’s sign), indicate SAP and are 
associated with increased risk of mortality, but they are seen only rarely. In a 
prospective study of 425 patients with AP, skin manifestations were present in 
1.2% of all AP patients and in 8% of SAP patients (Lankisch et al. 2009). 
2.3.3 LABORATORY EXAMS 
 
Amylase (preferably pancreas-specific) and lipase activities are used for early 
diagnosis of AP, but their levels are not associated with disease severity 
(Lankisch et al. 1999). Both amylase and lipase levels increase early after onset 
of AP, but amylase is quicker to return to normal. If there is a delay of 2-3 days 
before seeking treatment, amylase may be only slightly elevated or even 
normal. It has also been shown that in patients with alcohol-induced AP the 
amylase levels are lower than in other etiologic groups (Lankisch et al. 1999). 
Besides AP, amylase, including also pancreas-specific amylase, and lipase can 
be elevated in numerous other intra-abdominal diseases such as perforating 
duodenal ulcer, cholecystitis, ileus, diabetic ketoacidosis, appendicitis, kidney 
failure, some neoplasms, and macroamylasemia (Pieper-Bigelow et al. 1990). 
Alternative methods for early diagnosis of AP exist, but have limited 
availability. For example, urinary trypsinogen-2 dipstick is a rapid and non-
invasive method with an adequate diagnostic accuracy (Hedström et al. 1996, 
Kemppainen et al. 1997, Kylänpää-Bäck et al. 2000, Chang et al. 2012). 
To assess the severity of AP on admission, the following laboratory 
parameters are recommended: complete blood count, CRP, concentrations of 
electrolytes, creatinine, liver transaminases, alkaline phosphatase, blood 
glucose, coagulation status, and total albumin. If oxygen saturation is less than 
95% or the patient is tachypneic, arterial blood gas analysis is recommended 
(Lankisch et al. 2015).  
2.3.4 IMAGING 
 
CECT is the gold standard for diagnostic imaging, but early CT scan is 
recommended only when there is clinical doubt about the AP diagnosis, and 
other life-threatening disorders have to be excluded; it should not be used 
solely for severity assessment (Banks et al. 2013, Lankisch et al. 2015). The 
reasons for this are as follows: it takes several days before necrosis can be 
clearly defined; the morphologic changes are not directly proportional to the 
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severity of OD; in the early phase of AP, no treatments are required for fluid 
collections or pancreatic necrosis; and the predictive accuracy of CT scoring 
systems for determining the severity of AP is similar to that of clinical scoring 
systems (Bollen et al. 2012, Banks et al. 2013). Impaired kidney function and 
allergy are contraindications for the use of contrast medium.  
Non-enhanced MRI is comparable to CECT in the early assessment of 
severity of AP (Stimac et al. 2007), but MRI is better than CECT to distinguish 
solid masses from liquid component, and thus, may help in determining 
necrosis in the fluid collection (Banks et al. 2013). Transabdominal 
ultrasonography is the first-line imaging modality for detecting gallbladder 
stones, and magnetic resonance cholangiopancreatography (MRCP) for 
common bile duct stones (Giljaca et al. 2015, Gurusamy et al. 2015). A simple 
chest x-ray can show pleural effusions and pulmonary infiltrates.  
2.4 CLASSIFICATION OF ACUTE PANCREATITIS 
The Atlanta classification based on the Atlanta Symposium in 1992 is the 
standard classification system for AP severity, distinguishing mild and severe 
AP (Bradley 1993).  This classification was recently revised, now separating 
three different groups: mild, moderately severe, and severe (Table 2) (Banks 
et al. 2013). Patients with mild AP recover uneventfully and show no signs of 
organ dysfunction or exacerbation of chronic illness or any local complications 
on CECT. Patients with moderately severe AP develop local morphologic 
complications seen on CECT and/or exacerbation of chronic illness and/or 
transient OD that resolves within 48 hours. Patients with SAP suffer from 
persistent OD that lasts more than 48 hours. The presence of OD is assessed 
according to the Modified Marshall Score (MMS), where 2 points or more in 
any of the evaluated organ systems indicate OD (Marshall et al. 1995, Banks et 
al. 2013).  
Table 2. Revised Atlanta Classification (Banks et al. 2013). 
Clinical/radiological findings Severity of acute pancreatitis 
Mild Moderately severe Severe 
Uneventful recovery + - - 
Local complication on CT - -/+ -/+ 
Exacerbation of chronic illness - -/+ -/+ 
Organ dysfunction - -/transienta persistentb  
(always present) 
Abbreviations: CT, Computed tomography 
aOrgan dysfunction resolves within 48 hours 
bOrgan dysfunction persists for more than 48 hours 
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2.4.1 MORPHOLOGY 
 
According to the Revised Atlanta Classification (Banks et al. 2013), AP can be 
subdivided into two groups based on morphologic findings in CECT: (1) 
edematous pancreatitis with acute inflammation of the pancreatic 
parenchyma and peripancreatic tissues, but without recognizable tissue 
necrosis, and (2) necrotizing pancreatitis with acute inflammation associate 
with pancreatic parenchymal necrosis and/or peripancreatic necrosis. 
Different types of local complications occur upon odematous and necrotizing 
pancreatitis. In odematous pancreatitis a homogenous fluid collection without 
definable walls and adjacent to pancreas is called acute peripancreatic fluid 
collection. If acute peripancreatic fluid collection develops a well-defined 
encapsulated wall around itself, it is called a pancreatic pseudocyst. This takes 
usually more than four weeks. Necrotic collections associated with necrotizing 
pancreatitis include acute necrotic collection, which may eventually (after four 
weeks) mature into walled-off necrosis surrounded by a well-defined wall. 
Acute necrotic collection and walled-off necrosis may be intrapancreatic 
and/or extrapancreatic. Correct classification of a collection is required, since 
the treatment modalities may differ (Banks et al. 2013).   
2.4.2 EARLY AND LATE PHASE CLASSIFICATION 
 
During the first week of hospitalization (early phase) systemic 
complications define the treatment strategy. Systemic spread of the cytokines 
manifests clinically as SIRS. SIRS is present if at least two of the following 
features exist: temperature <36°C or >38°C; pulse >90 per minute; 
respiratory rate >20 breaths per minute; and white cell count <4 or >12 E9/l 
(American College of Chest Physicians 1992). Early SIRS and OD are rather 
common findings on admission to hospital, but often the host’s response to 
inflammation adapts to treatment, and in many patients the systemic signs of 
inflammation resolve within the first 48 hours of admission (Buter et al. 2002, 
Mofidi et al. 2006). About half of the SAP patients present with OD or develop 
it during the first 24 hours (Johnson et al. 2001, Mentula et al. 2003). Apart 
from AP-associated OD, a pre-existing comorbidity may also be exacerbated 
by AP. If this happens, AP is classified as moderately severe (Banks et al. 2013).  
Persistent OD that does not resolve within 48 hours is the defining feature of 
SAP.  
The later phase overlaps with the early phase, but generally starts after the 
second week and may last for weeks or months. The late phase is characterized 
by persistence of systemic signs of inflammation or the presence of local 
complications. During this phase the local complications gradually become 
encapsulated and may require treatment. Therefore, defining the morphologic 
characteristic of local complications by radiologic imaging becomes important 
(Banks et al. 2013). Even though the cellular signs of CARS or 
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immunosuppression may be present already on admission (Kylänpää-Bäck et 
al. 2001a, Mentula et al. 2003), the infectious clinical complications usually 
develop in the later phase (Beger et al. 1986) as a result of bacterial 
translocation from gut lumen into the circulation (Capurso et al. 2012).  
Mortality in SAP is largely associated with the development of MODS and 
infected pancreatic necrosis (Halonen et al. 2002, Johnson and Abu-Hilal 
2004, Petrov et al. 2010). MODS generally follows a predictable course, 
beginning with the lungs and followed by hepatic, intestinal, and renal 
dysfunction. Hematologic and myocardial failure usually occur later, whereas 
central nervous system dysfunction may occur early or late. Disorders of the 
immunologic system occur early at the cellular level (Kylänpää et al. 2005). 
Over the last years, the mortality in AP has declined; recently, an overall 
mortality rate of only 0.9% was reported in the United States (Krishna et al. 
2017). Recent studies show the mortality rates in relation to the severity of AP 
as 0% in mild AP, 0-3% in moderately severe AP, and 15-59% in SAP (Nawaz 
et al. 2013, Zubia-Olaskoaga et al. 2016). Development of MODS substantially 
increases the risk of death. While in the presence of a single OD the mortality 
rate is less than 10%, in the presence of MODS it rises to 35-50% (Pandol et al. 
2007). Mortality is biphasic. Half of the deaths occur within the early phase 
due to early MODS (McKay and Imrie 2004) and the other half in the late 
phase most often due to septic complications. Also in late mortality early 
MODS is a predisposing risk factor (Isenmann et al. 2001, Buter et al. 2002).  
2.5 TREATMENT OF ACUTE PANCREATITIS 
2.5.1 CONSERVATIVE TREATMENT 
 
Fluid therapy 
The early treatment of AP includes early fluid resuscitation, supplemental 
oxygen, analgesia, and nutritional support (Lankisch et al. 2015). Although 
fluid therapy is considered a cornerstone of early treatment, evidence of its 
positive effects is based on animal models showing that AP compromises 
splanchnic perfusion and pancreatic microcirculation (Gardner et al. 2008). A 
recent systematic review claimed the current evidence of fluid therapy to be 
paltry and of poor quality, and several important questions, such as the type 
of fluid, the rate of administration, and how fluid therapy should be guided, 
remain to be answered (Haydock et al. 2013). Recent guidelines (Tenner et al. 
2013, Working Group IAP/APA Acute Pancreatitis Guidelines 2013) suggest 
that early aggressive fluid therapy is most beneficial within the first 12-24 
hours, preferably with Lactate Ringer’s solution. It is crucial to assess the 
response to fluid therapy every 6 hours for at least 24-48 hours. 
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Nutrition 
Among all AP patients, early enteral feeding is recommended, and parenteral 
nutrition is administered only in rare cases when enteral feeding is not 
tolerated. Provision of enteral feeding has been shown to downregulate 
systemic immune responses, reduce oxidative stress, reduce the rate of 
infections, and improve patient outcome compared with total parenteral 
nutrition (McClave and Heyland 2009, Al-Omran et al. 2010). In mild AP 
without severe pain, nausea, or vomiting, oral feeding may be restarted 
without delay. In SAP, enteral tube feeding through nasojejunal or nasogastric 
tube is recommended for patients who do not tolerate oral feeding by day 3 to 
day 5 (Forsmark et al. 2016).  
 
Antibiotics 
Although much debated, the current guidelines state that antibiotic 
prophylaxis is not recommended in AP, unless infection is suspected or has 
been confirmed (Tenner et al. 2013, Working Group IAP/APA Acute 
Pancreatitis Guidelines 2013). If infected pancreatic necrosis is diagnosed or 
strongly suspected, use of broad-spectrum antibiotics covering both Gram-
positive and Gram-negative bacteria of the normal intestinal flora, which is a 
common source of infection (Beger et al. 1986), is advised.  
2.5.2 INVASIVE TREATMENT 
 
Abdominal compartment syndrome 
Normal intra-abdominal pressure is < 12 mmHg, whereas intra-abdominal 
pressure of 12-20 mmHg is defined as intra-abdominal hypertension, and 
intra-abdominal pressure > 20 mmHg with new onset of OD as abdominal 
compartment syndrome. In SAP, different studies show the incidence for 
intra-abdominal hypertension to be 60-80% and that for abdominal 
compartment syndrome 25-50% (De Waele and Leppäniemi 2009). First-line 
treatment is conservative decompression with nasogastric drainage and rectal 
tubes, if necessary, along with prokinetics, depletion of volume overload, and 
drainage of ascites. Also adequate analgesia and sedation to decrease 
abdominal muscle tone should be provided. Only if these fail and intra-
abdominal pressure is constantly > 25 mmHg with new onset of OD, surgical 
decompression should be performed (Mentula et al. 2010, Working Group 
IAP/APA Acute Pancreatitis Guidelines 2013).  
 
Infected necrosis 
Indications for radiological, endoscopic, or surgical intervention in necrotizing 
pancreatitis are infected necrosis with clinical deterioration and, or in the 
absence of documented infected necrosis, ongoing OD for several weeks after 
the onset of AP. There is a consensus that endoscopic or surgical intervention, 
Review of the literature 
42 
if necessary, should be delayed until 4 weeks after onset of AP to allow the 
collection to mature and become “walled-off” (Working Group IAP/APA Acute 
Pancreatitis Guidelines 2013). In addition to open necrosectomy, mini-
invasive necrosectomy techiques have emerged, such as endoscopic 
transgastric necrosectomy (Seifert et al. 2009), and a “step-up approach” that 
comprises placement of percutaneous catheters, followed by minimally 
invasive necrosectomy if necessary (van Santvoort et al. 2010). 
 
Other reasons 
Besides infected necrosis, ongoing gastric outlet or intestinal or biliary 
obstruction due to mass effect, forming large uninfected walled-off necrosis, 
may require intervention, preferably 4-8 weeks after onset of AP. Acute 
bleeding or bowel ischemia are acute situations that require emergency 
laparotomy (Working Group IAP/APA Acute Pancreatitis Guidelines 2013). 
Pseudoaneurysms are rare, but potentially serious complications of AP. They 
are treated through mesenteric angiography with transcatheter arterial 
embolization (Lankisch et al. 2015). In mild biliary pancreatitis, early 
cholecystectomy during the same hospital admission is advised (da Costa et al. 
2015). In necrotizing AP, it is recommended to delay cholecystectomy for 6 
weeks, until active inflammation subsides and fluid collections resolve or 
stabilize (Working Group IAP/APA Acute Pancreatitis Guidelines 2013). If a 
patient is unfit for surgery, endoscopic sphincterotomy is recommended 
(Lankisch et al. 2015). Early ERCP is recommended only in severe biliary 
pancreatitis and subsequent cholangitis due to biliary obstruction (Tse and 
Yuan 2012).  
2.6 PREDICTING THE SEVERITY OF ACUTE 
PANCREATITIS 
Besides making an accurate diagnosis of AP at the emergency department and 
starting optimal care, it is crucial to assess the severity of AP to determine 
which patients will have SAP, requiring earlier triage to intermediate care or 
ICU and earlier initiation of effective therapy. On the other hand, the limited 
ICU resources should be allocated wisely (Lilja et al. 2008). Clinical 
assessment has been shown to correctly identify only one-third of SAP patients 
on admission (Wilson et al. 1990). Therefore, several clinical and laboratory 
markers and various scoring systems have been evaluated as optimal 
predictive markers for the first 48 hours.  
2.6.1 CLINICAL FACTORS AND SCORING SYSTEMS 
 
Clinical factors that increase the risk of complications or death include age ≥ 
60 years, comorbidity, alcohol use, smoking, body mass index > 30 kg/m2, 
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and type 2 diabetes mellitus (Yadav and Lowenfels 2013). Several CT scoring 
systems based on either non-enhanced or contrast-enhanced CT studies exist, 
but according to the current knowledge an early CT is not routinely 
recommended solely for severity assessment since the predictive accuracy is 
similar to clinical scoring systems (Bollen et al. 2012).  
Clinical scoring systems, such as the Acute Physiology and Chronic Health 
Evaluation II, the Glasgow-Imrie Score, the Ranson Score, the Harmless Acute 
Pancreatitis Score, and the Bedside Index for Severity in Acute Pancreatitis, 
combine several clinical, radiographic, and laboratory findings. However, they 
are complex and cumbersome to use in clinical practice, and they all offer only 
moderate accuracy in predicting persistent OD, i.e. SAP, with individual 
laboratory markers, such as creatinine, providing similar accuracy (Mounzer 
et al. 2012).  
2.6.2 CONVENTIONAL LABORATORY MARKERS 
 
Conventional laboratory markers already in clinical use, such as creatinine, 
hematocrit or calcium, may predict SAP, but they are considered to reflect 
rather than predict OD. An increase in serum creatinine or hematocrit level 
results from intravascular volume depletion. Rising creatinine level that does 
not respond to adequate fluid resuscitation indicates an increased risk of 
severe AP (Yang et al. 2014), and after 48 hours of admission, creatinine level 
≥ 159 μmol/L has been demonstrated to be associated with the development 
of pancreatic necrosis (Muddana et al. 2009). Hematocrit ≥44 % on admission 
predicts SAP (Koutroumpakis et al. 2015). Hypocalcemia may result from 
sequestration of circulating calcium and albumin into the extracellular space 
due to increased microvascular permeability (Bhattacharya et al. 1985), and 
hypocalcemia has been shown to predict SAP on admission to hospital 
(Mentula et al. 2005) and in ERCP patients within 48 hours of the procedure 
(Kawa et al. 2000).  
2.6.3 MARKERS OF INFLAMMATION 
 
CRP is a major acute-phase protein produced in the liver in response to 
proinflammatory cytokines such as IL-1β and TNF. The levels of CRP rise 
during both bacterial infection and sterile inflammation, but the generic 
function of CRP in different diseases is not yet fully understood. During 
inflammation CRP has been shown to opsonize damaged cells, including 
nuclear breakdown products, such as chromatin and histones, to facilitate 
their clearance (Abrams et al. 2013). CRP predicts SAP (Puolakkainen et al. 
1987), but it peaks with a delay of 48-72 hours after symptom onset, and 
therefore, it is not usually applicable as a predictor of SAP on admission to 
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hospital. CRP value ≥ 150 mg/L at 48 hours after onset of symptoms indicates 
SAP (Dervenis et al. 1999).  
Several cytokines and their receptors have been evaluated extensively in AP 
patients as predictors of SAP. Of these, TNF-α, IL-6, IL-8, and IL-10 are 
among the most studied markers. TNF-α is a crucial cytokine in the 
pathogenesis of inflammatory reactions, serving as a proximal mediator of 
inflammation and inducing production of further cytokines, such as IL-6 and 
IL-8, and it has been shown to predict SAP (Pooran et al. 2003, Surbatovic and 
Radakovic 2013). However, detecting elevated TNF-α levels in the circulation 
is challenging due to the rapid hepatic clearance, and also contradictory 
studies showing no predictive value exist (Paajanen et al. 1995, Digalakis et al. 
2009). Many studies report IL-6 as a predictor of SAP (Viedma et al. 1992, 
Brivet et al. 1999, Mentula et al. 2005, Fisic et al. 2013), and as an inducer of 
acute-phase response IL-6 peaks earlier than CRP (Heath et al. 1993).  While 
several studies show IL-8 to predict SAP (Gross et al. 1992, Shokuhi et al. 
2002, Fisic et al. 2013), conflicting results also exist (Mayer et al. 2000). 
According to a meta-analysis by Aoun et al. (2009), IL-6 and IL-8 seem to 
perform at an acceptable level, although IL-6 may be better than IL-8 on day 
1. IL-10 is a potent anti-inflammatory cytokine, and several studies show its 
predictive value in SAP (Brivet et al. 1999, Simovic et al. 1999, Mentula et al. 
2005).   
In addition to the above-mentioned cytokines, at least HGF (Ueda et al. 
1996, Espinosa et al. 2011, Sporek et al. 2013), G-CSF (Müller et al. 2000), 
IL-1β, (Mentula et al. 2005), IL-1 receptor antagonist  (Mentula et al. 
2005, Mayer et al. 2000), growth-related oncogene alpha (Shokuhi et 
al. 2002), IL-18 (Rau et al. 2001), monocyte chemoattractant protein 
(MCP) 1 (Rau et al. 2003), macrophage migration inhibitory factor 
(Sakai et al. 2003), IL-12 (Gregoric et al. 2014), and IL-15 (Ueda et al. 2007) 
in humans, and granulocyte macrophage colony-stimulating factor 
in experimental AP (Frossard et al. 2002) have revealed predictive value in 
SAP. Some studies show also soluble IL-2 receptor as a predictor of SAP 
(Pezzilli et al. 1994, Mayer et al. 2000), but others do not (Kylänpää-Bäck et 
al. 2001b).   
Procalcitonin is already available in clinical practice as a diagnostic 
marker of sepsis in critically ill patients (Wacker et al. 2013). In patients with 
AP procalcitonin may predict SAP (Kylänpää-Bäck et al. 2001b, Modifi et al. 
2009), but its role is more established in predicting infected pancreatic 
necrosis and fatal outcome (Rau et al. 2007, Modifi et al. 2009). Serial daily 
procalcitonin measurements show the procalcitonin levels to fall with clinical 
improvement both in sepsis (Karlsson et al. 2010) and in AP (Rau et al. 2007, 
Modifi et al. 2009).  However, procalcitonin assay is currently quite expensive, 
which may hinder its clinical use. 
Soluble urokinase-type plasminogen activator receptor, a 
marker of systemic inflammation, has shown promising results in predicting 
outcome of critically ill patients (Donadello et al. 2014), being superior to CRP 
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and procalcitonin (Backes et al. 2012, Uusitalo-Seppälä et al. 2012). Only 
recently, Nikkola et al. (2017) established it as a predictor of non-mild AP, and 
Lipinski et al. (2017) as a predictor of SAP, MODS, and fatal AP.   
Pentraxin 3, a soluble PRR for innate immunity and an acute-phase 
protein released from the inflammation site, is another potential research tool 
in the field of critically ill patients (Zhang et al. 2010), showing similar value 
as procalcitonin in predicting severe sepsis and fatal outcome (Uusitalo-
Seppälä et al. 2013). In patients with AP, pentraxin 3 has been demonstrated 
to be associated with the severity of AP and to reach peak values before CRP 
(Kusnierz-Cabala et al. 2013). In the recent study by Deng et al. (2017) that 
evaluated a vast array of cytokines and conventional biomarkers as predictors 
of SAP, pentraxin 3 was revealed as an independent predictor of SAP, 
predicting also development of SAP in patients with SIRS on admission.  
Aligned with the theory that endothelial activation and injury are crucial 
events in the pathogenesis of AP, endothelial markers, such as intercellular 
adhesion molecule 1, E-selectin and P-selectin, have been shown to be 
elevated in AP and to be associated with OD (Kaufmann et al. 1996, Powell et 
al. 2001, Zhu and Jiang 2012, Dabrowski et al. 2014, Chen et al. 2017), 
although contrary findings also exist (Kylänpää-Back et al. 2001b).  
In addition, von Willebrand factor was recently demonstrated to be 
associated with MODS in AP (Chen et al. 2017). CD73/ecto-5’-
nucleotidase is an enzyme that generates adenosine, which dampens 
inflammation and improves vascular barrier function. The activity of the 
soluble form of CD73 has been reported to be inversely correlated with the 
severity of AP and to predict SAP, more importantly already before the clinical 
signs of OD have developed (Maksimow et al. 2014). The regulator of vascular 
permeability, angiopoietin 2, is associated with persistent OD and SAP 
(Whitcomb et al. 2010). 
Additional inflammatory markers predicting SAP include CD11b, an 
activation marker of monocytes and macrophages (Kylänpää-Bäck et al. 
2001a), complement regulator protein CD59 (Lindström et al. 2008), 
matrix metalloproteinase 8 (Nukarinen et al. 2016), and matrix 
metalloproteinase 9 (Chen et al. 2006).  
Cellular signs of immunosuppression may arise early in SAP and have been 
revealed to have prognostic value. Decreased HLA-DR expression on 
monocytes is associated with AP severity and predicts the development of OD 
(Kylänpää-Bäck et al. 2001a, Mentula et al. 2003, 2004). Also a reduced 
number of circulating lymphocytes, inversely proportional to the 
severity of AP, has been shown (Curley et al. 1993, Pezzilli et al. 1995, 
Pietruczuk et al. 2006, Dambrauskas et al. 2010).  
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2.6.4 CELL DEATH MARKERS 
 
Of DAMPs as predictors of SAP, HMGB1 is the most studied marker (Yasuda 
et al. 2006, Kocsis et al. 2009, Li et al. 2017), and also a receptor for HMGB1 
(but also for several other ligands), namely soluble form of receptor for 
advanced glycation end products has been shown to have significantly 
higher levels in SAP patients with persistent OD compared to milder attack 
(Lindström et al. 2009). Few clinical studies show also cell-free DNA 
(Gornik et al. 2011, Kocsis et al. 2009) and histones (Liu et al. 2017) as 
predictors of SAP. Circulating nucleosomes have been shown to predict OD 
among a cohort of ICU patients including also patients with AP (Chen et al. 
2012).   
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3 PRESENT INVESTIGATION 
3.1 AIMS OF THE STUDY 
The main goal of the study was to identify predictors of SAP in AP patients 
without OD on admission to hospital. Specific aims were as follows: 
 
I. To evaluate the predictive value of 48 circulating cytokines for 
SAP in AP patients without OD on admission.  
 
II. To validate circulating IL-8 and HGF as predictors of SAP in 
an independent cohort of AP patients without OD on 
admission, and to investigate whether IL-8 and HGF predict 
persistent OD in AP patients with OD on admission. 
 
III. To determine whether circulating nucleosomes predict SAP in 
AP patients without OD on admission.  
 
IV. To examine whether similar aberrations in leukocyte signaling 
occur in sepsis and SAP, and whether they are associated with 
the severity of AP and the presence of OD. 
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3.2  MATERIALS AND METHODS 
3.2.1 PATIENTS AND HEALTHY CONTROLS 
 
All of the studies include prospective series of non-consecutively enrolled 
patients. In Studies I-III, all patients had AP, and Study IV comprises both AP 
and sepsis patients. Healthy volunteers recruited from hospital and laboratory 
personnel served as controls in Studies II and IV. Study II had 32 healthy 
controls (20 men and 12 women, median age 46 years, range 21-71), and Study 
IV 28 healthy controls (19 women and 8 men, median age 35 years, range 24-
68). The Surgical Ethical Review Board of the Joint Authority for the Hospital 
District of Helsinki and Uusimaa approved all study protocols, and a written 
informed consent was obtained from each patient or the next of kin. Healthy 
controls gave verbal informed consent.  
AP patients were admitted to Helsinki University Hospital within 72 hours 
(Studies I, III, IV) or within 96 hours (Study II) of symptom onset and were 
recruited within the first few days after hospital admission. Patients with a 
known history of chronic pancreatitis were excluded. Sepsis patients were 
recruited within 48 hours of hospital admission. Exclusion criteria were 
concomitant malignancy, known immunological deficiency, and in-hospital 
sepsis. Clinical characteristics and outcome of patients in Studies I-IV are 
shown in Table 3.  
3.2.2 CLASSIFICATION AND DEFINITIONS 
 
Acute pancreatitis 
AP diagnosis was based on at least two of the following three features: typical 
epigastric pain with elevated pancreatic specific plasma amylase level of more 
than three times the upper limit of normal, and/or typical findings in 
abdominal CT scan or MRI (Tenner et al. 2013). According to routine hospital 
practice, early imaging was usually performed without intravenous contrast 
medium to preserve renal function. The severity of AP was assessed according 
to the outcome of AP using the Revised Atlanta Classification (Banks et al. 
2013) as mild, moderately severe, or severe. The presence of OD on admission 
was assessed according to the MMS (Marshall et al. 1995), as recommended in 
the Revised Atlanta Classification (Banks et al. 2013); MMS ≥2 from one of the 
evaluated organ systems indicates OD and MMS <2 no OD (Table 4).  Patient 
classification in Studies I-IV is shown in Table 5.  
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Table 3. Patient characteristics in Studies I-IV.  
Characteristic Study I, 
n = 163 
Study II,  
n = 176 
Study III,  
n = 74a 
Study IV, n = 18 
AP,  
n = 18 
Sepsisb,  
n = 14 
Study period 6/2003 –
1/2008 
3/2011 – 
8/2014 
6/2003 – 
1/2008 
2/2010 – 5/2012 
Men, n (%) 120 (74) 122 (69) 57 (77) 11 (61) 8 (57) 
Age, yearsc 48 (39-57) 51 (43-64) 48 (39-59) 53 (46-75) 62 (50-65) 
Time between onset 
of symptoms and 
admission, hoursc 
24 (12-48) 24 (12-48) 24 (12-48) 30 (8-72) NA 
Etiology of AP 
Alcohol, n (%) 
Biliary, n (%) 
Other, n (%) 
Unknown, n (%) 
 
113 (69.3) 
35 (21.5) 
11 (6.7) 
4 (2.5) 
 
110 (63) 
37 (21) 
29 (17)d 
 
 
54 (73) 
14 (19) 
3 (4) 
3 (4) 
 
11 
5 
0 
2 
 
NA 
NA 
NA 
NA 
Mortality, n (%)  8 (4.9) 2 (1) 8 (11) 1 (6) 3 (21) 
Abbreviations: AP, Acute pancreatitis; NA, Not applicable. 
aCohort of AP patients included in Study I 
bEtiology of sepsis was pneumonia (n=7), intra-abdominal infection (n=5), or cervical abscess 
(n=1).  
cValues are in median (interquartile range) 
dOther or unknown 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRESENT INVESTIGATION 
50 
Table 4. Modified Marshall Score (Marshall et al. 1995, Banks et al. 2013) 
Organ system Score 
0 1 2 3 4 
Respiratory 
(Pa2/FiO2), mmHg 
>400 301-400 201-300 101-200 ≤101 
Renala (serum 
creatinine, μmol/L) 
<134 134-169 170-310 311-439 >439 
Cardiovascular 
(systolic blood 
pressure, mmHg)b 
>90 <90, fluid-
responsive 
<90, not 
fluid-
responsive 
<90, 
pH<7.3 
>90, pH<7.2 
For non-ventilated patients, the FiO2 can be estimated as follows: Room air, 21%; 2 l/min, 25%; 4 
l/min, 30%; 6-8 l/min, 40%; 9-10 l/min, 50%. 
A score of 2 or more in any system indicates the presence of organ dysfunction. 
aA score for patients with pre-existing chronic renal failure depends on the extent of further 
deterioration of baseline renal function. No formal correction exists for a baseline serum creatinine 
≤134 μmol/L. 
bOff inotropic support. 
 
 
 
Table 5. Classification of patients with acute pancreatitis in Studies I-IV 
Study Severity of acute pancreatitisa 
Mild Moderately severe Severe 
No ODb 
(MMS<2), n 
No ODb 
(MMS<2), n 
With ODb 
(MMS≥2), n 
No ODb 
(MMS<2), n 
With ODb 
(MMS≥2), n 
I 103 25 10 14 11 
II 121 23 9 10 13 
III 23 21 6 14 10 
IV 9 6 0 2 1 
Abbreviations: MMS, Modified Marshall Score; OD, Organ dysfunction. 
aOutcome of acute pancreatitis according to the Revised Atlanta Classification (Banks et al. 2013)  
bOn admission according to the MMS (Marshall et al. 1995) 
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Sepsis 
The diagnosis of sepsis was based on the 1992 sepsis definitions (Bone et al. 
1992), but the severity of sepsis was classified according to recent guidelines 
(Singer et al. 2016) as sepsis and septic shock. Sepsis is defined as a life-
threatening OD (an increase in the Sequential organ failure assessment score 
of 2 points or more) caused by a dysregulated host response to infection (Table 
6). Septic shock entails a need for a vasopressor to maintain mean arterial 
pressure of 65 mmHg or more and serum lactate level greater than 2 mmol/L 
in the absence of hypovolemia.  
 
Table 6. Sequential Organ Failure Assessment Score (Vincent et al. 1996). 
Variable Score 
0 1 2 3 4 
Respiratory      
PaO2/FiO2, 
mmHg 
>400 ≤400 ≤300 ≤200a ≤100a 
Coagulation 
platelets, 
x103/μL 
>150 ≤150 51-100 21-50 ≤20 
Liver 
bilirubin, μmol/L 
<20 20-32 33-101 102-204 >204 
Cardiovascular, 
hypotension 
No 
hypotension 
MAP <70 
mmHg 
Dop ≤5 or 
dob (any 
dose)b 
Dop >5, 
epi≤0.1, or 
norepi≤0.1b 
Dop>15, 
epi>0.1 or 
norepi 0.1b 
Central 
nervous 
system, GCS 
5 13-14 10-12 6-9 <6 
Renal 
creatinine, 
μmol/L or urine 
output, mL/day 
<110 110-170 171-299 300-440  
(or <500 
ml/d) 
>440  
(or <200 
mL/d) 
Abbreviations: Dob, Dobutamine, Dop, Dopamine, Epi, epinephrine; FiO2, Fraction of inspired 
oxygen, GCS, Glasgow Coma Score; MAP, Mean arterial pressure; Norepi; Norepinephrine; PaO2, 
Arterial partial pressure of oxygen 
aValues are with respiratory support. 
bAdrenergic agents administered for at least one hour (doses given are in μg/kg per minute). 
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3.2.3 SAMPLING AND ANALYTICAL METHODS 
 
The blood samples were taken on admission after recruitment. For Study I, we 
used serum, for Studies II and III plasma, and for Study IV whole blood. The 
samples were stored at -70°C — -80°C to await analyses, except for Study IV, 
where the samples were analyzed within three hours of sampling.  
The predictive values of the conventional markers CRP (Studies I-III), 
creatinine (Studies I-III), and calcium (Study I) were used for comparison 
because they have established prognostic value in AP (Puolakkainen et al. 
1987, Mentula et al. 2005, Muddana et al. 2009). These values were 
determined according to the hospital’s routine practice (Helsinki University 
Hospital Laboratory, HUSLAB).  
 
Multiplex detection technique (Study I)  
In Study I, the serum levels of 48 cytokines were determined by magnetic bead 
suspension array (20 μl of each sample) using Multiplex detection technology. 
Bio-Plex Pro Human Cytokine 21- and 27-plex panels (Bio-Rad Laboratories, 
Hercules, CA, USA) were used according to the manufacturer’s instructions, 
except that the assay reagents were used at half of their recommended 
concentrations. The 21-plex panel and the 27-plex panel contained the 
cytokines shown in Table 7. The samples were analyzed using the Bio-Plex 200 
System, and the results were calculated using Bio-Plex Manager 6.0 software 
(Bio-Rad Laboratories). Values of interferon gamma were below the detectable 
limit in all patients, and thus, it was excluded from data analyses. In addition, 
the majority of values for leukemia inhibitory factor, eotaxin, granulocyte 
colony-stimulating factor, IL-1α, IL-3, IL-12p40, IL-15, and TNF-β were below 
detectable limits, and they were scored dichotomically as detectable or 
undetectable.  
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Table 7. Cytokine levels analyzed in 21-plex and 27-plex panels using Multiplex detection 
technology in Study I. 
21-plex panel 27-plex panel 
β-NGF Beta nerve growth factor FGF Basic fibroblast growth factor 
CTACK Cutaneous T cell attracting 
chemokine 
Eotaxin Eotaxin 
GRO-α Growth-regulated oncogene alpha G-CSF Granulocyte colony-
stimulating factor 
HGF Hepatocyte growth factor GM-CSF Granulocyte macrophage 
colony-stimulating factor 
IFN-α2 Interferon alpha 2 MIP-1α Macrophage inflammatory 
protein 1 alpha 
IL-1α Interleukin 1 alpha MIP-1β Macrophage inflammatory 
protein 1 beta 
IL-2Rα Interleukin 2 receptor α chain MCP-1 Monocyte chemoattractant 
protein 1 
IL-3 Interleukin 3 IL-1β Interleukin 1 beta 
IL-12p40 Interleukin 12p40 IL-1Ra Interleukin 1 receptor 
antagonist 
IL-16 Interleukin 16 IL-2  Interleukin 2 
IL-18 Interleukin 18 IL-4 Interleukin 4 
LIF Leukemia inhibitory factor IL-5 Interleukin 5 
M-CSF Macrophage colony-stimulating 
factor 
IL-6  Interleukin 6 
MIF Macrophage migration inhibitory 
factor 
IL-7  Interleukin 7 
MCP-3 Monocyte chemoattractant protein 3 IL-8  Interleukin 8 
MIG Monokine induced by interferon 
gamma 
IL-9 Interleukin 9 
SCF Stem cell factor IL-10 Interleukin 10 
SCGF- β Stem cell growth factor beta IL-12p70  Interleukin 12p70 
SDF-1α Stromal cell-derived factor 1 alpha IL-13  Interleukin 13 
TNF-β Tumor necrosis factor-beta IL-15  Interleukin 15 
TRAIL TNF-related apoptosis-inducing 
ligand 
IL-17A Interleukin 17A 
  IFN-γ Interferon gamma 
  IP-10 IFN-gamma-induced protein 
10 
  PDGF-BB Platelet-derived growth factor, 
two BB chains 
  RANTES Regulated on activation, 
normal T cell expressed, and 
secreted 
  TNF-α Tumor necrosis factor alpha 
  VEGF Vascular endothelial growth 
factor 
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Enzyme-linked immunosorbent assay (Studies II-IV) 
In Studies II and IV, IL-8 and HGF plasma levels were determined with 
cytokine-specific enzyme-linked immunosorbent assay (ELISA) using 
reagents from BD Biosciences, Erembodegem, Belgium (IL-8) and 
R&DSystems Europe Ltd., Abingdon, UK (HGF). For Study II, the detection 
limits and inter-assay coefficients of variation were 0.8 pg/ml and 5.0% for IL-
8 and 7.8 pg/ml and 5.6% for HGF, respectively. In 17 of the 176 patients in 
Study II, the HGF levels were below the detectable limit, and these values were 
extrapolated as 0.002 ng/ml (one-fifth of the lowest HGF value determined). 
All IL-8 results fell within the standard range of IL-8 ELISA. In Study IV, the 
detection limits and inter-assay coefficients of variation were 0.8 pg/ml and 
1.4% for IL-8 and 7.8 pg/ml and 7.1% for HGF, respectively.  
In Study III, nucleosomes were quantified with Cell Death Detection 
ELISAPLUS (Roche, Basel, Switzerland) according to the manufacturer’s 
instructions. The results are presented as absorbance units (AUs), and 
negative values are recorded as zero. Since the plasma samples for this study 
were collected between June 2003 and January 2008, and the nucleosome 
measurements were performed in the year 2013, we checked that there was no 
correlation between sample age and nucleosome level in mild, moderately 
severe, or severe AP (Spearman’s r=0.31, p=0.153; r=0.02, p=0.928; and 
r=0.10, p=0.631, respectively). 
 
Flow cytometry (Study IV) 
In Study IV, the target molecule phosphorylation was determined by means of 
phosphospecific whole blood flow cytometry, the method first described by our 
group in 2008 concerning STAT1 phosphorylation in circulating monocytes 
(Vakkila et al. 2008). In the studies by Oiva et al. (2010a, 2010b, 2013), this 
method was used to investigate NF-ĸB, STAT1, STAT3, STAT5, STAT6, and 
p38 and ERK1/2 MAPKs, in monocytes, lymphocytes, and neutrophils of SAP 
patients. In the current study, we chose to determine NF-ĸB, STAT1, STAT3, 
and ERK1/2 MAPK phosphorylation in non-stimulated and stimulated 
monocytes, lymphocytes, and neutrophils of sepsis and AP patients. The 
stimulation strategy was as follows: NF-ĸB stimulation by E. coli and LPS in 
monocytes and neutrophils and by TNF in each of the three cell types; STAT1 
and STAT3 by IL-6 in each cell type, and ERK1/2 MAPK by the combination 
of PMA and Ca2+ -ionophore A23187 in each cell type.  
A 4-ml venous blood sample was collected into a Falcon polypropylene tube 
(Becton Dickinson, Lincoln Park, NJ, USA) supplemented with pyrogen-free 
citrate phosphate dextrose (Baxter Health Care Ltd., Norfolk, England, 0.1 
ml/ml blood) and kept at room temperature until stimulations within three 
hours of sampling. Each patient sample was compared with a sample obtained 
from a healthy volunteer within two weeks.  
Monoclonal antibodies against cell surface structures used for surface 
marker staining comprised fluorescein isothiocyanate conjugated anti-CD14 
(clone clone 0IPIgG2b) and phycoerythrin conjugated anti-HLA-DR (clone 
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L243, IgG2a) and its isotype control (mouse IgG2a). Monoclonal antibodies 
for intracellular phosphospecific labeling included AlexaFluor647-conjugated 
anti-pNF-ĸB p65 (pS529) (clone K10-895.12.50, IgG2b), anti-STAT1 (pY701) 
(clone 4a, IgG2a), anti-ERK1/2 (pT202/pY204) (clone 20A, IgG1), and 
phycoerythrin conjugated anti-STAT3 (pY705) (clone 4/P-STAT3, IgG2a). All 
antibodies were from Becton-Dickinson Biosciences (San Jose, CA, USA). 
The recombinant cytokines TNF and IL-6 were obtained from R&D 
(Minneapolis, MN, USA).  PMA and Ca2+-ionophore A23187, and E.coli O11:B4 
LPS were from Sigma (St. Louis, MO, USA). Whole E. coli bacteria were 
purchased from The National Institute for Health and Welfare (Helsinki, 
Finland), grown in brain heart infusion medium, pelleted, and washed twice. 
A diluted culture was made to quantify viable bacteria. The bacteria were 
pelleted, resuspended in glycerol-tryptone soya broth medium, and stored at -
70°C. The stimuli were diluted in phosphate-buffered saline before use.  
The blood sample was divided into 100-μl aliquots in Falcon polystyrene 
tubes (Becton Dickinson, Lincoln Park, NJ, USA). Next, the tubes were 
supplemented either with TNF 10 ng/ml (final concentration), IL-6 100 
ng/ml, PMA + A23187 each 1 μg/ml for 5 min, LPS 100 ng/ml, or E. coli (50 
cells/leukocyte) for 10 min at 37oC. Reference tubes were left without 
stimulus.  
After incubations, leukocyte fixation, red cell lysis, and leukocyte 
permeabilization were performed according to Becton Dickinson Phosflow 
Protocol III for Human Whole Blood. After permeabilization, the samples 
were washed with Beckton Dickinson Pharmingen Stain Buffer and 
resuspended in 100 μl of the buffer. Aliquots of AlexaFluor647- and 
phycoerythrin labelled phosphospecific Abs and anti-CD3-PerCP were added. 
The samples were incubated for 20 min in the dark at room temperature, 
washed, resuspended in 300 μl of the buffer, stored in the dark on ice, and run 
on the flow cytometer within three hours.  
Data acquisition and analysis were carried out by FACSCanto II flow 
cytometer with FACSDiva software (Becton Dickinson Sciences, San Jose, CA, 
USA). The anti-CD14- fluorescein isothiocyanate label was used for identifying 
monocytes. Neutrophils and lymphocytes were first delineated according to 
their light scattering properties, and strongly CD14-fluorescein isothiocyanate 
positive events were excluded using electronic gates. AlexaFluor647 and 
phycoerythrin histograms were developed from stimulated and non-
stimulated monocytes, neutrophils, and lymphocytes.  
Flow cytometric data on the intracellular targets were determined as 
follows: First, the median of relative fluorescence units (RFU) of all cells of a 
given leukocyte population indicates whether the target molecule 
phosphorylation is aberrant relative to healthy controls. The aberration can be 
caused by a different size of the normally responding cellular subpopulation, 
which is shown by the proportion (%) of positively fluorescing cells, or a 
different capability of the responding cells to raise the target phosphorylation, 
which is shown by the average RFU of the proportion of positive fluorescing 
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cells. The proportion of the positively fluorescing cells and their median RFU 
were measured using a threshold method. In brief, an electronic gate covering 
the brightest fluorescing cells was set manually to comprise less than but as 
close as possible to 5% of the cells in the non-stimulated sample, and the same 
gate was used to determine the proportion of positively fluorescing cells in the 
respective stimulus-treated sample. Thus, values < 5% indicate that the cells 
have not responded to the stimulus.  
Constitutive STAT3 phosphorylation was measured as the proportion of 
constitutively STAT3-phosphorylated cells (pSTAT3+ %) and their median 
RFU. In brief, a marker was set on each cell population histogram of the 
healthy subject’s sample so that it includes less than but as close as possible to 
5% of the brightest events, and the markers were then copied to the respective 
patient’s sample histograms. 
The proportion of HLA-DR-positive monocytes was determined as 
described previously (Kylänpää-Bäck et al. 2001a). 
3.2.4 STATISTICAL ANALYSIS 
 
Statistical analyses were performed using IBM SPSS® Statistic versions 19 
and 22 (SPSS, Chicago, IL, USA) statistical software. Because of the skewness 
of the data, non-parametric tests were used. The results are given as median 
and interquartile range (IQR) or range if n≤3, or number of patients and 
percentages. Correlations between two continuous variables were tested using 
Spearman rank correlation (r = correlation coefficient). Comparisons for 
continuous variables between two groups were made using Mann-Whitney U 
test. Jonckheere-Terpstra test for trend test was used for comparisons 
between three ordered groups. P values ≤ 0.05 were considered significant, 
and double-sided tests were used. P values of multiple comparisons were 
corrected using the Bonferroni method. 
The predictive value of a biomarker (Studies I-III) and a combined 
regression model (Studies I and II) was first assessed using a receiver operator 
characteristic (ROC) curve and calculating the area under the curve (AUC), 
ranging from 0-1. AUC 1.0 is a perfect test, and AUC 0.5 is similar to tossing a 
coin. Then, the optimal cut-off value of a biomarker was determined from the 
curve. An optimal predictive marker has both high specificity and high 
sensitivity. Since ICU beds are limited in real hospital life and should be 
allocated wisely, we figured that a useful marker should have high specificity, 
preferably ≥ 90%. We therefore chose a “clinically optimal” cut-off value from 
the ROC curve where the longest increase in the sensitivity of the slope 
declines, and the specificity is ≥ 90%. For the optimal cut-off value, we 
calculated, apart from specificity and sensitivity, positive and negative 
likelihood ratio and diagnostic odds ratio (Glas et al. 2003) with 95% 
confidence intervals (Newcombe 1998). Univariate logistic regression analysis 
was used for identifying significant predictors of SAP, and multivariate logistic 
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regression analysis with forward conditional stepping was used, when 
appropriate, to identify independent predictors of SAP. Here, p<0.005 
inclusion and p>0.10 removal criteria were used to select a variable into the 
model. 
3.3 RESULTS 
3.3.1 PREDICTORS OF DEVELOPMENT OF SEVERE ACUTE 
PANCREATITIS (I-III) 
3.3.1.1 Circulating cytokines (I) 
 
Of the 48 cytokines (Table 7) screened in the whole AP cohort as potential 
predictors of SAP on admission, 14 showed significantly higher levels in SAP 
than in non-SAP when Bonferroni-adjusted p values were used (p<0.001) 
(Table 8). A significant difference (p<0.05) between the non-SAP and SAP 
group was found also for CRP, creatinine, and calcium (data not shown). The 
levels of all 14 cytokines correlated with each other (Spearman’s r ≥0.21 for all, 
p≤0.007), and the correlation was especially strong between IL-6 and either 
IL-8, G-CSF, MCP-1, HGF, or macrophage colony-stimulating factor (r >0.6, 
p<0.001). The median time between onset of symptoms and hospital 
admission was 24 hours in all AP patients (Table 3), and it did not differ 
between non-SAP and SAP groups (data not shown, p=0.450).  
A forward stepping logistic regression analysis of those 14 cytokines 
revealed only IL-6 and HGF as independent predictors of SAP (p=0.006 and 
p<0.001, respectively). When calcium, creatinine, and CRP were added into 
the logistic regression analysis with IL-6 and HGF, calcium was also an 
independent predictor of SAP (p=0.023). The AUCs of IL-6, HGF, and calcium 
to predict SAP were 0.87 (95% CI 0.81-0.94), 0.81 (0.72-0.90), and 0.81 (0.70 
to 0.91), respectively. Using the clinically optimal cut-off value (specificity 
≥90%), IL-6 >501.6 pg/mL, HGF >3020.1 pg/mL, and calcium <1.91 mmol/L 
predicted SAP with sensitivities of 48% (30-67%), 60% (41-77%), and 58% 
(36-77%), positive likelihood ratios of 7.4 (3.5-15.6), 8.3 (4.2-16.3), and 8.5 
(4.1-17.8), and diagnostic odds ratios of 13.2 (4.7-37.3), 19.2 (6.9-53.6), and 
18.8 (6.0-58.4), respectively.    
The patients presenting without OD (MMS<2) were analyzed further. Of 
these, 14/142 developed SAP during hospitalization. The median time between 
onset of symptoms and hospital admission was 24 hours (IQR 12- 48 hours), 
which did not differ significantly between non-SAP and SAP groups (data not 
shown, p=0.161). Of the 14 cytokines showing a significant difference between 
non-SAP and SAP patients in the whole AP cohort, only HGF, IL-8, and G-CSF 
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showed a significant difference in patients without OD on admission (MMS<2) 
(Table 8). Of the conventional markers (CRP, creatinine, calcium), only 
calcium levels differed significantly (p<0.001) between non-SAP and SAP 
patients (data not shown). In the ROC curve analysis HGF, IL-8, and G-CSF 
predicted SAP with AUCs of 0.83, 0.79, and 0.78, respectively (Figure 6, Table 
9). Calcium performed equally well, with AUC of 0.74 (Table 9). Here, we used 
the cut-off values obtained from the whole patient cohort to determine the 
statistical performances of a biomarker (Table 9). Due to the limited number 
of SAP patients (n=14) in this subgroup, we did not perform a multivariate 
analysis, but instead determined how many of the SAP patients could be 
identified using a single cytokine or a combination of them. HGF and IL-8 
performed equally, both correctly identifying 4/14 SAP patients. G-CSF 
identified one additional SAP patient (5/14). The best combination of the 
markers was that of IL-8 and HGF, meaning that if either of the markers was 
above the cut-off level, 8/14 of the SAP patients were correctly identified as 
having SAP before they developed OD.  
 
 Receiver operating characteristic curves for the combined logistic regression 
model of IL-8 and HGF, and CRP in predicting severe acute pancreatitis among 
patients without OD on admission (n=142). The arrows show the clinically optimal 
cut-off values (specificity ≥ 90 %) used to calculate the statistical performance of the 
biomarkers for Table 9. Abbreviations: CRP, C-reactive protein; HGF, Hepatocyte 
growth factor; IL, Interleukin; MMS, Modified Marshall Score; OD, Organ dysfunction.
PRESENT INVESTIGATION 
60 
3.3.1.2 IL-8 and HGF (II) 
 
In Study II, the predictive value of IL-8 and HGF for development of SAP was 
evaluated in another cohort of AP patients and among healthy controls using 
a cytokine-specific ELISA. The median levels of circulating IL-8 and HGF were 
very low among healthy controls (7.0 pg/mL, IQR 6.1-8.9 and 0.002 ng/mL, 
IQR 0.002-0.18, respectively), and they differed significantly (p<0.001) from 
the patients with AP (32.1 pg/mL, IQR 18.5-71.2 and 0.56 ng/mL, IQR 0.14-
0.81, respectively). IL-8 and HGF levels were associated with the severity of 
AP (p<0.001 for both) and correlated with each other (Spearman’s r =0.514, p 
<0.001). 
Of the 176 patients, 154 had no OD (MMS<2) on admission, but of these, 
10 developed SAP during hospitalization. The median time between onset of 
symptoms and hospital admission was 24 hours (IQR 12-48 hours) and it did 
not differ significantly between non-SAP and SAP groups (data not shown, 
p=0.835). A significant difference (p<0.05) between non-SAP and SAP was 
found for IL-8 and HGF (data not shown). In the ROC curve analysis, IL-8, 
HGF, and their combined logistic regression model predicted SAP with AUCs 
of 0.73, 0.79, and 0.82, respectively (Figure 8, Table 9).  
 
 Receiver operating characteristic curves for the combined logistic regression 
model of IL-8 and HGF, IL-8, HGF, and CRP in predicting severe acute 
pancreatitis among patients without OD on admission (n=154). The arrows 
show the clinically optimal cut-off values (specificity ≥ 90 %) used to calculate the 
statistical performance of the biomarkers for Table 9. Abbreviations: CRP, C-
reactive protein; HGF, Hepatocyte growth factor, IL, Interleukin, MMS, Modified 
Marshall Score; OD, Organ dysfunction. 
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The diagnostic performances of the markers at the clinically optimal cut-
off level are presented in Table 9. The results show that combining the markers 
did not improve the model. The univariate regression analysis revealed IL-8 > 
120.9 pg/mL, HGF > 1.66 ng/mL, and CRP > 268 mg/L, but not creatinine 
(cut-off > 100 μmol/L), as significant predictors of SAP, with the odds ratios 
of 11.0 (95% CI 2.8-43.4), 13.6 (3.4-54.1), 8.8 (1.4-55.1), and 3.8 (0.7-20.3), 
respectively. 
3.3.1.3 Circulating nucleosomes (III) 
 
In the whole AP cohort, the median time between onset of symptoms and 
hospital admission was 24 hours (Table 3), and it did not differ significantly 
between non-SAP or SAP patients (data not shown, p=0.833). Nucleosome 
levels increased along with the severity of AP (p<0.001) and were significantly 
higher (p=0.002) in SAP (0.30 AU, IQR 0.17-0.45) than in non-SAP (0.07 AU, 
IQR 0.02-0.22). Nucleosome levels were also significantly higher (p=0.019) in 
non-survivors (0.38 AU, IQR 0.19-077) than in survivors (0.09 AU, IQR 0.02-
0.27). 
Nucleosomes, CRP, and creatinine predicted SAP with AUC of 0.72 (95% 
CI 0.58-0.86), 0.77 (0.65-0.87), and 0.67 (0.58-81), respectively. Using the 
clinically optimal cut-off value (specificity ≥ 90 %), nucleosomes > 0.57 AU, 
creatinine > 110 μmol/L, and CRP > 264 mg/L predicted SAP with sensitivities 
of 21% (9-40%), 46% (28-65%), and 33% (18-53%), positive likelihood ratios 
of 5.2 (1.1-24.9), 5.2 (2.0-13.4), and 3.8 (1.4-10.4), and diagnostic odds ratios 
of 6.3 (1.1-35.4), 8.8 (2.6-29.8), and 5.2 (1.5-18.1), respectively. In the forward 
stepping multivariate logistic regression analysis (gender-adjusted), only 
creatinine ≥ 110 μmol/L was an independent predictor of SAP with an odds 
ratio of 6.2 (95% CI 1.7-21.9) (p=0.005).  
Among the 58 patients without OD (MMS<2) on admission, 14 developed 
SAP during hospitalization. The median time between onset of symptoms and 
hospital admission was 24 hours (IQR 12- 48 hours), and it did not differ 
significantly between non-SAP and SAP patients (data not shown, p=0.101). 
Nucleosomes, creatinine and CRP predicted SAP with AUCs of 0.65, 0.67, and 
54, respectively (Figure 8, Table 9). The diagnostic performances of the 
nucleosomes, creatinine, and CRP are shown in Table 9. The forward stepping 
multivariate logistic regression analysis (gender-adjusted) of the biomarkers 
revealed only nucleosomes as an independent predictor of SAP with an odds 
ratio of 1.2 (95% CI 1.2-899.5) (p=0038).         
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 Receiver operating characteristic curves for nucleosomes, creatinine, and CRP 
in predicting severe acute pancreatitis among patients without OD on 
admission (n=58). The arrows show the clinically optimal cut-off values (specificity 
≥ 90 %) used to calculate the statistical performance of the biomarkers for Table 9. 
Abbreviations: CRP, C-reactive protein; MMS, Modified Marshall Score; OD, Organ 
dysfunction. 
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3.3.2 PREDICTORS OF PERSISTENT ORGAN DYSFUNCTION IN 
ACUTE PANCREATITIS (I-III) 
 
In Study I, 21/163 patients had OD (MMS ≥ 2) on admission. The median time 
between onset of symptoms and hospital admission was 33 hours (IQR 24-54 
hours) in patients with transient OD and 48 hours (24-72 hours) in those with 
persistent OD, but the difference was not significant (p=0.349). Of the 14 
cytokines showing significant difference between non-SAP and SAP in the 
whole AP patient cohort (Table 8), only the HGF levels differed significantly 
between patients with persistent OD (n=11) and transient OD (n=10), 
p=0.007; the difference was not significant after applying the Bonferroni 
method (p≤0.001 is significant) (Table 10).  
         
Table 10. Biomarker levels among patients with organ dysfunction (MMS≥2) on admission. 
Biomarker Transient OD  
(<48 hours) 
n Persistent OD  
(≤48 hours) 
n p value 
Study I      
   HGF 2212.2 (1855.4-4703.2) 10 5293.5 (3933.2-8194.2) 11 0.006a (NS) 
   IL-8 69.5 (41.4-124.2) 10 102.3 (82.4-217.7) 11 0.061a (NS) 
Study II      
   HGF 0.58 (0.38-2.3) 9 1.56 (1.06-5.33) 13 0.030 
 52.7 (20.6-95.2) 9 165.6 (102.6-741.7) 13 0.004 
Study III      
   Nucleosomes 0.41 (0.18-0.71) 6 0.39 (0.24-0.75) 10 0.635 (NS) 
Abbreviations: HGF, Hepatocyte growth factor; IL, Interleukin; NS, Not significant; OD, Organ 
dysfunction. 
aIn study I p≤0.001 is significant when Bonferroni correction is applied. 
Data denote median (interquartile range). 
 
In Study II, 22/176 patients had OD (MMS≥2) on admission.  Both IL-8 and 
HGF levels were significantly higher in patients with persistent OD (n=13) 
relative to those with transient OD (n=9) (Table 10). In the ROC curve analysis, 
IL-8, HGF, and their combined logistic regression model predicted SAP with 
AUCs of 0.86, 0.78, and 0.84, respectively (Figure 9, Table 11), but CRP and 
creatinine did not, with respective AUCs of only 0.43 and 0.36. Combining IL-
8 and HGF did not improve the model (Figure 9, Table 11). At the clinically 
optimal cut-off level, IL-8 showed a better sensitivity than HGF, and in the 
univariate analysis only IL-8 (cut-off > 130.9 pg/mL) was an independent 
predictor of SAP with an age-adjusted odds ratio of 40.3 (95% CI 1.7-938.2). 
In patients with persistent OD, the median time between onset of symptoms 
 65 
and hospital admission was significantly shorter than in those with transient 
OD (12 hours; IQR 9-12 hours vs. 24 hours; IQR 18-59; p=0.036). However, 
in the univariate analysis, it was not a statistically significant predictor of SAP 
(OR 0.948; 95% CI 0.898-1.001; p =0.056).  
 
 
 ROC curve for IL-8, HGF, and their combination to predict severe acute pancreatitis 
among patients with OD on admission (n=22) in Study II. The arrows show the 
clinically optimal cut-off values (specificity ≥ 90%) used to calculate the statistical 
performance of the biomarkers for Table 11. Abbreviations: HGF, Hepatocyte growth 
factor; IL, Interleukin; MMS, Modified Marshall Score; OD, Organ dysfunction. 
In Study III, 16/74 patients presented with OD (MMS≥2). The median time 
from onset of symptoms to hospital admission did not differ significantly 
between patients with transient OD (n=6) and patients with persistent OD 
(n=10) (data not shown, p=0.792). There was also no significant difference in 
the nucleosome levels (Table 10).
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3.3.3 LEUKOCYTE SIGNALING PROFILES IN SEPSIS AND ACUTE 
PANCREATITIS (IV) 
 
In AP patients, the median time between onset of symptoms and hospital 
admission was 30 hours (Table 3), and it did not differ significantly between 
mild, moderately severe AP, or SAP (data not shown, p=0.309). Although on 
hospital admission only one SAP patient had OD (Table 5), at blood sampling 
(which occurred 22-44 hours later) all three of them had OD (MMS≥2). 
Creatinine, IL-8, and HGF levels increased along with the severity of AP 
(p<0.05 for all), unlike CRP (p=0.296) (data not shown). 
In sepsis patients, the information regarding the time between onset of 
symptoms and hospital admission was not routinely reported in the medical 
charts. These patients were admitted to the ICU (where sampling occurred) 
within 32 hours of hospital admission (median 7 hours).  
 
NF-ĸB  
In monocytes and lymphocytes of both sepsis and AP patients, NF-ĸB 
signaling activity was depressed after ex vivo stimulation, shown both as a 
lower proportion of positively fluorescing cells (pNF-ĸb+%) and their lower 
pNF-ĸB fluorescence intensities compared to healthy controls (Table 12). In 
AP patients’ neutrophils, pNFĸb+% was lower than in healthy controls. 
 
STAT1  
In IL-6 stimulated monocytes of both sepsis and AP patients, pSTAT1+% and 
the respective pSTAT1 fluorescence intensity were lower than in healthy 
controls (Table 13). In IL-6 stimulated lymphocytes, pSTAT1+% was lower in 
sepsis and AP patients than in healthy controls. 
 
STAT3 
The STAT3 signaling pathway was constitutively activated without stimulus in 
monocytes, neutrophils, and lymphocytes of both sepsis and AP patients, but 
not in healthy controls (Table 13). In IL-6 stimulated samples of sepsis and AP 
patients, the pSTAT3+% and the corresponding fluorescence intensity were 
lower in monocytes and higher in neutrophils, and in IL-6 stimulated 
lymphocytes of sepsis patients, pSTAT3+% was higher than in controls. 
 
ERK1/2 MAPK  
In PMA+A23187 stimulated monocytes of both sepsis and AP patients, the 
pERK1/2 fluorescing intensity was lower than in healthy controls (Table 14). 
In PMA+A23187 stimulated neutrophils of sepsis patients, pERK1/2+% was 
higher than in healthy controls. In the lymphocytes of AP patients, 
pERK1/2+% and the corresponding fluorescence intensity were lower than in 
healthy controls
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Association with the severity of acute pancreatitis 
Table 15 shows the signaling pathways that (i) differed significantly between 
healthy controls and AP patients, and (ii) associated with the severity of AP. 
Of these, pSTAT1+% in monocytes and lymphocytes, promoted by IL-6, 
correlated inversely with the severity of AP, as did pSTAT3 RFU in monocytes. 
On the contrary, pSTAT3 RFU of IL-6 stimulated neutrophils increased along 
with the severity of AP. Additionally, constitutive STAT3 phosphorylation of 
unstimulated neutrophils, shown as the proportion of positively fluorescing 
cells, correlated with disease severity. None of the NF-ĸB or ERK 1/2 signaling 
aberrations was associated with the severity of AP (p for trend >0.085). 
 
Discriminating patients with organ dysfunction from those 
without organ dysfunction  
Six signaling markers, (1) pSTAT1+% and (2) pSTAT3 RFU in IL-6 stimulated 
monocytes, (3) pSTAT3 RFU in IL-6 stimulated neutrophils, (4) pSTAT3+% 
and (5) pSTAT3 RFU in unstimulated neutrophils (constitutive activation), 
and (6) pSTAT1+% in IL-6 stimulated lymphocytes, were identified as 
potential markers in discriminating OD patients (sepsis or SAP) from those 
without OD (mild or moderately severe AP) (Table 16). They met the following 
criteria: (i) a significant difference between healthy controls and sepsis or (ii) 
between healthy controls and AP patients, and (iii) were associated with the 
severity of AP (Tables 13 and 15).  
Of these, only pSTAT3 RFU of IL-6 stimulated monocytes was significantly 
lower in OD patients than in no-OD patients and could potentially serve as a 
marker (Table 16). IL-8 and HGF levels were significantly higher in OD 
patients than in no-OD patients.   
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3.4 DISCUSSION 
3.4.1 PREDICTING SEVERE ACUTE PANCREATITIS (I-III) 
 
Cytokines (I, II) 
Cytokines are important inflammatory mediators that play an essential part in 
the development of the systemic manifestations of AP, and they are detected 
in the circulation early after the onset of AP (Norman 1998, Mentula et al. 
2005). Therefore, their ability to predict the course of AP has been of great 
interest since the early 1990s. Despite extensive studies on cytokines, a 
clinically useful marker to predict SAP remains obscure in terms of reliability, 
utility, and cost. Challenges in human studies include the variation between 
the onset of symptoms and hospital admission together with the rapid kinetics 
of cytokines. Indeed, the production of cytokines peaks 36-48 hours after 
symptom onset and then usually rapidly declines (Norman 1998). An 
exception may be the production of IL-8, which has been shown to continue 
for days or even weeks (Remick 2005). There is also a substantial 
heterogeneity in cytokine response between individuals (Wurfel et al. 2005). 
All of the above can markedly affect the cytokine levels of a single patient and 
make it difficult to determine reliable cut-off values to predict SAP. Combining 
the markers may reduce these effects, but the time-consuming analytical 
methods with high costs have usually restricted the number of studied 
cytokines to only a few at a time.  
To the best of our knowledge, Study I comprises the largest number of 
cytokines (n=48) evaluated together in a group of AP patients, which was 
possible due to the Multiplex detection technique. This is a technique that 
enables multiplex screening of dozens of cytokines in small-volume samples 
rapidly and automatically. Here, we found that only IL-6 and HGF predicted 
SAP in all AP patients. This result is in accordance with previous studies since 
both IL-6 (Aoun et al. 2009) and HGF (Ueda et al. 1996, Espinosa et al. 2011, 
Sporek et al. 2013) have been demonstrated to be predictors of SAP. However, 
our main focus was to identify markers in the subgroup of patients without OD 
on admission since including also those having OD on admission most 
probably enhances the performance of the markers. In the current study, we 
found that IL-8, HGF, and G-CSF predicted SAP in AP patients without OD on 
admission. Of the clinical markers or symptoms, only calcium predicted SAP. 
Along with HGF, both IL-8 (Aoun et al. 2009) and G-CSF (Müller et al. 2000) 
have been shown to be predictors of SAP. However, to the best of our 
knowledge, this is the first study evaluating cytokines as predictors of SAP 
where AP patients without OD on admission were analyzed separately.  
The results of Study I concerning IL-8 and HGF were further confirmed in 
Study II with cytokine-specific ELISA. Although in Study I the combined 
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logistic regression model of IL-8 and HGF provided better sensitivity than 
either of the markers alone, the result was not duplicated in Study II. This may 
be due to the significant correlation between the cytokines.  
Another approach in the present investigations was to analyze the patients 
with OD on admission and to determine whether any of the cytokines could 
identify the patients with transient OD from those with persistent OD already 
in the early phase of AP. This approach was chosen because early OD is a rather 
common finding on admission to hospital, but in many patients it will resolve 
within the first 48 hours after admission (Buter et al. 2002, Mofidi et al. 2006). 
In Study II, IL-8 was shown to predict persistent OD, i.e. SAP. In Study I, the 
levels of HGF were higher among patients with persistent OD than in patients 
with transient OD, but the difference was not significant after the p value was 
corrected using the Bonferroni method. Moreover, these findings may not be 
relevant in terms of clinical practice since a patient with OD needs optimal 
care and monitoring preferably in the ICU, and it is not known whether the 
resolution of OD is due to early supportive care or the natural course of AP.  
The results of Studies I and II together show IL-8 and HGF to be predictors 
of SAP in AP patients without OD on admission. In patients with OD on 
admission, IL-8 may identify those with SAP, i.e. distinguish patients with 
persistent OD from those with transient OD.  
 
Nucleosomes (III) 
One interesting group of potential early markers is the circulating DAMPs that 
are released during cell injury and promote inflammation. In Study III, we 
chose to evaluate the predictive value of circulating chromatin in the form of 
nucleosomes using a commercial ELISA assay. Although cell-free DNA has 
been shown to predict SAP in human AP (Kocsis et al. 2009), and elevated 
nucleosome levels have been found in experimental AP (Kang et al. 2014b) and 
in patients with sepsis (Zeerleder et al. 2003), previously, circulating 
nucleosome levels have not been systematically investigated in AP patients.  
In Study III, we showed that nucleosome levels are associated with the 
severity of AP and predict SAP among all patients, and, more importantly, 
among those without OD on admission.  The mechanisms that account for the 
enhanced levels of circulating nucleosomes are manifold, and their origin in 
AP, or in other diseases, is not yet clear, but possible sources include damaged 
acinar cells (Kang et al. 2014b), other injured organs, and dying neutrophils 
through NETosis (Marsman et al. 2016).  
3.4.2 LEUKOCYTE SIGNALING IN SEPSIS AND ACUTE 
PANCREATITIS (IV) 
 
Despite different triggering mechanisms, SAP and sepsis share, at least in part, 
common immunopathogenetic mechanisms (Wilson et al. 1998, Dib et al. 
2003, Koussoulas et al. 2006), and recent papers connect the definitions of 
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both SAP (Banks et al. 2013) and sepsis (Singer et al. 2016) closely to the 
presence of (persistent) OD instead of the old and inaccurate SIRS criterion 
(Churpek et al. 2015). Still, AP guidelines (Working Group IAP/APA Acute 
Pancreatitis Guidelines 2013) suggest that the AP patients with SIRS on 
admission should be treated as if they have SAP. Clearly, there is an urgent 
need for more reliable predictive markers of SAP on admission to hospital. 
The activation of intracellular signaling in blood leukocytes precedes 
generation of soluble mediators, such as cytokines. Therefore, it represents a 
very early stage of systemic inflammatory response, and the aberrations in 
leukocyte signaling could potentially reveal early novel markers to predict SAP 
or sepsis, i.e. persistent OD. The previous studies by our group (Oiva et al. 
2010a, 2010b, 2013) showed multiple aberrations in signaling pathways of 
blood leukocytes in a cohort of SAP patients complicated by OD.  
In the current study, we showed that in sepsis the aberrations in the NF-
ĸB, STAT1, STAT3, and ERK1/2 MAPK pathways largely resemble those 
discovered earlier in SAP by Oiva et al. (2010a, 2010b, 2013). The findings 
were similar despite the different time-points in blood sampling.  While in the 
studies by Oiva et al. (2010a, 2010b, 2013) the sampling occurred usually only 
after the first hospital week, i.e. in the late phase of AP, in the current study 
the samples were taken within 48 hours of hospital admission. Secondly, we 
analyzed in a group of AP patients whether the aberrations correlated with the 
severity of AP, and revealed STAT1 and STAT3 as potential new predictive 
markers of SAP. Thirdly, we analyzed in the combined group of AP and sepsis 
patients whether any of the markers would distinguish patients with persistent 
OD from those without persistent OD and found that only IL-6-induced 
STAT3 phosphorylation levels in monocytes were significantly lower in the 
persistent OD group. The OD groups were also distinguished by IL-8 and HGF 
levels. 
Depressed activity of the NF-ĸB pathway was found in ex vivo stimulated 
monocytes and lymphocytes of sepsis patients relative to healthy controls, as 
seen in SAP with OD (Oiva et al. 2010a, 2010b). Previous studies using 
electrophoretic mobility shift assay of blood mononuclear cells support these 
findings, showing activation of NF- ĸB both in sepsis (Böhrer et al. 1997, 
Arnalich et al. 2000, Abraham 2005) and in AP (Satoh et al. 2003, O’Reilly et 
al. 2006, Rakonczay et al. 2008). Although Satoh et al. (2003) showed also 
that NF-ĸB activity was reduced in the peripheral blood mononuclear cells of 
SAP patients when exposed to LPS, patients but not in mild AP patients, our 
findings did not correlate with the severity of AP. Together, these results 
suggest that although NF-ĸB pathway is a master regulator of inflammation 
and its reduced activity is a sensitive marker of systemic inflammation, it may 
not serve as a useful predictive marker of SAP.  
Previously, IL-6 induced phosphorylation of STAT1 has been demonstrated 
to be reduced in activated mouse T cells (Teague et al. 2000, Van De Wiele et 
al. 2004). This is in accordance with the current study showing that STAT1 
activity was reduced in IL-6 stimulated monocytes and lymphocytes of sepsis 
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patients relative to the cells of healthy controls, a finding also reported in the 
SAP patients of Oiva et al. (2010a, 2010b). Since STAT1 is associated with the 
development of Th1-mediated tissue injury, our finding may reflect a shift 
from Th1 to Th2-type response, which has been established to occur in both 
sepsis (Ferguson et al. 1999, Li et al. 2015) and AP (Ueda et al. 2002, 
Pietruczuk et al. 2006). In the present study, the IL-6 induced 
phosphorylation level of STAT1 in monocytes and the proportion of STAT1 
positive lymphocytes correlated inversely with the severity of AP. Therefore, 
STAT1 may provide a useful predictive marker of SAP in patients with AP. 
In the present study, IL-6 induced STAT3 phosphorylation was reduced in 
sepsis patients’ monocytes, but enhanced in their neutrophils relative to 
healthy controls. Previously, Oiva et al. (2010a and 2013) reported similar 
findings in SAP. Both reduced STAT3 activity in monocytes and enhanced 
STAT3 activity in neutrophils correlated with the severity of AP. The opposite 
findings between monocytes and neutrophils may reflect more prominent 
anti-inflammatory or immunosuppressive mechanisms in monocytes, while 
the enhanced STAT3 phosphorylation in neutrophils can be explained by 
STAT3 activation-related priming, which has previously been described in 
sepsis patients (Tamassia et al. 2008).  
In addition, the current study showed that STAT3 pathway was 
constitutively activated in sepsis patients’ monocytes, neutrophils, and 
lymphocytes before adding a stimulus. In the studies by Oiva et al., STAT3 
pathway was constantly activated in lymphocytes (2010b) and in some 
patients’ neutrophils (2013), but not in monocytes (2010a). The different 
finding regarding monocytes may indicate that constitutive activation of 
STAT3 pathway is an early event in monocytes and it disappears as the disease 
progresses. In the current study, STAT3 pathway was constitutively activated 
also in AP patients’ monocytes, neutrophils and lymphocytes, but the finding 
associated with the severity of AP only in neutrophils. Previously, constitutive 
activity of STAT3 pathway has been shown to occur in sepsis (Tamassia et al. 
2008), other inflammatory conditions (Kuuliala et al. 2015), and malignant 
cells (Aggarwal et al. 2009). The cause may involve increased circulating levels 
of STAT3-activating cytokines such as IL-6 (Kuuliala et al. 2015). In contrast, 
in normal cells the activity of a signaling pathway is a tightly controlled 
mechanism with several feedback systems and interactions between different 
pathways, and the pathway is usually activated only for a short period of time 
(Aaronson and Horvath 2002, Scott et al. 2002).  
Phosphorylation of ERK1/2 MAPK was reduced in PMA+A23187 
stimulated monocytes in sepsis, a finding also reported by Oiva et al. (2010a) 
in SAP. In the present study, we did not detect an association with the severity 
of AP. 
Taken together, we found in the current study that the signaling 
aberrations in the NF-ĸB, STAT1, STAT3, and ERK1/2 MAPK pathways in 
patients with sepsis largely resemble those discovered previously in patients 
with SAP (Oiva et al. 2010a, 2010b, 2013). A novel finding was that the 
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aberrations in STAT1 and STAT3 pathways associate with the severity of AP 
and those in STAT3 pathway with the presence of OD. It is an intriguing 
question whether STAT1 and STAT3 could serve as early markers for 
predicting the development of OD, but this possibility requires further studies.  
3.5 STRENGTHS AND LIMITATIONS OF THE STUDY  
Studies I-III 
The approach in Studies I-III is a novel and clinically meaningful; identifying 
the predictive markers of SAP in patients without OD on admission reveals the 
true performance of the markers in everyday hospital life. Previously, to the 
best of our knowledge, a similar approach has been used only in the study of 
Maksimow et al. (2014) showing soluble CD73 activity to predict SAP. In 
addition, applying various statistical methods and presenting ROC curve, 
AUC, sensitivity, specificity, positive and negative likelihood ratio, and 
diagnostic odds ratio with respective 95% confidence intervals show the 
predictive capacity of the markers from several angles and may be considered 
a methodological strength. Furthermore, choosing cut-off values with high 
specificity (≥ 90%) is more representative of the everyday hospital life, with a 
constant battle for limited ICU resources, than the traditional method utilizing 
conventional cut-offs that maximize the sum of sensitivity and specificity.  
Study limitations include at least the following: First, the number of SAP 
patients, especially those without OD on admission, was limited, resulting in 
a wide range of 95% confidence intervals and excluding any firm conclusions 
being drawn from the subgroup data. Secondly, the cut-off values were 
obtained from the same population in which their predictive value was 
analyzed. This post hoc analysis is known to exaggerate the results (Sternby et 
al. 2016); a more reliable analysis of the markers would necessitate the use of 
a validation cohort. Although the predictive performances of IL-8 and HGF 
revealed in Study I were re-evaluated in Study II using an independent cohort 
of AP patients, the cut-off values cannot be compared due differences in 
analytical methods. A third limitation is the relatively long storage time of the 
samples, especially in Studies I and III, before cytokine and nucleosome 
measurements, which may markedly affect their reported levels. Most 
cytokines are stable for up to 2 years of storage, but after 4 years several 
cytokines are degraded (de Jager et al. 2009). Long-term stability 
investigations of nucleosomes have revealed a 7% decrease per year in serum 
levels of nucleosomes during sample storage at -70°C (Holdenrieder et al. 
2010). This limitation was taken into account in Study III, where we analyzed 
whether the storage time correlated with the nucleosome level in mild, 
moderately severe, or severe AP, and found no correlation.  
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Study IV 
When interpreting the results of Study IV, their preliminary nature must be 
taken into account. The number of patients is very limited, consisting of only 
a few AP patients in different severity categories. Therefore, we could not 
perform a subgroup analysis among patients without OD on admission, and 
obviously, the associations between the altered signaling pathways and the 
severity of AP must be investigated in a larger group of AP patients. 
Additionally, the study was not planned to address questions about the 
ultimate pathophysiological impacts of the aberrant signaling pathways, but 
rather to identify possible predictive markers. Overall, leukocyte signaling 
constitutes a complex network of signaling pathways that work in close 
collaboration with each other, and the ultimate impacts of a signaling pathway 
via altered gene transcription are numerous. As an example, the impacts of 
STAT3 pathway are numerous since it activates over 3000 genes in T cells 
(Durant et al. 2010).  
The leukocyte signaling profile determinations also have limitations. 
Firstly, we did not monitor cell viability. However, it is known that cell damage 
may increase non-specific binding of antibodies to the cell membrane (Bohn 
1976), and susceptibility to membrane injury and cell viability may differ 
between blood leukocytes of AP or sepsis patients and healthy controls 
(Giamarollos-Bourboulis et al. 2006). Furthermore, cell viability and different 
modes of cell death, including apoptosis and necroptosis, may be associated 
with the severity of AP and sepsis; systematic studies are needed to explore 
this possibility.  
3.6 FUTURE ASPECTS 
Predictive biomarkers 
Predicting SAP reliably on admission to hospital is an enormous challenge. 
One of the hurdles is the rapid evolution of OD. The incidence of OD rapidly 
increases by the second and third day after onset of symptoms, and about half 
of the patients have OD on admission to hospital or develop it during the first 
24 hours after admission (Johnson et al. 2001, Mentula et al. 2003). However, 
the other half of SAP patients does not have OD on admission, thus 
constituting a clinical challenge for correct severity prediction. At the moment, 
the economic burden of mild AP is also substantial (Peery et al. 2015) since all 
AP patients need preferably at least a few days’ follow-up in the hospital to 
determine whether AP will resolve or become complicated. Therefore, a 
predictive marker with reasonable accuracy is also needed for mild AP 
(Sternby et al. 2017).  
The rapid evolution of OD encourages us to identify very early markers of 
systemic inflammation that would predict SAP reliably already within the first 
24 hours after onset of symptoms. Besides being future potential targets for 
immune therapy, from a clinical perspective we should be able to identify early 
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the SAP patients without OD on admission to triage them accordingly. 
Potential novel early markers of systemic inflammation include aberrations in 
intracellular leukocyte signaling pathways since the activity of a signaling 
pathway precedes e.g. cytokine production. Also DAMPs, as they are released 
from damaged cells at the onset of AP and promote inflammation, have 
potential to serve as very early predictors. Indeed, a component of 
nucleosomes, namely circulating free histone levels, has been shown to rise 
within 2 hours after the onset of experimental AP (Ou et al. 2015), and was just 
recently shown to predict persistent OD with a somewhat better accuracy than 
IL-6 or IL-8 within 48 hours of symptom onset (Liu et al. 2017). Additionally, 
novel markers of systemic inflammation arising from sepsis studies, such as 
pentraxin 3 and soluble urokinase-type plasminogen activator receptor, have 
recently shown promising results as early predictors of SAP (Deng et al. 2017, 
Lipinski et al. 2017). Future studies re-evaluating the novel promising 
predictive markers of SAP should, first of all, contain large consecutive series 
of AP patients including a reasonable proportion of SAP patients (preferably 
those without OD on admission) presenting early after onset of symptoms 
(preferably within 24 hours).  
Although we are still searching for an optimal predictive marker of SAP, it 
is more than likely that especially the individual differences in immune 
response make it virtually impossible to identify a marker that would possess 
clinically relevant predictive ability on its own. As improved analytical 
methods, such as multicytokine arrays, enable multiple detection of a large 
number of biomarkers simultaneously, combining them may enhance their 
accuracy as predictors of SAP. However, due to the significant correlations 
between many cytokine levels, more accurate results may be obtained by 
combining markers reflecting different phenomena in the pathogenesis of AP. 
In the future, along with constant advancements in technology and 
accumulating knowledge of systems biology in the fields of genomics, 
epigenetics, transcriptomics, proteomics, and metabolomics (as reviewed by 
Skibsted et al. 2013), it may well be that we will have a combination of 
thousands of molecular signals to help in accurate risk stratifying.   
Additionally, with the increasing amount of analytical data, we will need 
more intelligent methods to analyze it. Besides the traditional methods, such 
as logistic regression models, the possibilities of a commercially available 
artificial neural network have already been tested in AP studies (Halonen et al. 
2003, Andersson et al. 2011). Using the artificial neural network, it is possible 
to select from a large number of potential variables the inputs needed to create 
the most accurate model. Thus far, the AP studies have focused on currently 
available clinical and laboratory markers and the number of evaluated 
variables has been limited to a maximum of 23 (Andersson et al. 2011). 
However, the artificial neural network, as a step towards artificial intelligence, 
has performed better than the conventional logistic regression models.  
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Treatment 
Currently, all AP patients are treated identically, and the interventions are 
symptom-related since there is no specific therapy for AP. Along with the 
improved understanding of the immune response during AP and sepsis, great 
hope has been placed on the immunomodulatory treatment as a future therapy 
to improve the outcome of such patients either by attenuating the early 
proinflammatory response or by abolishing the subsequent 
immunosuppression. However, the results of many clinical studies have been 
disappointing (Johnson et al. 2001, Kyhälä et al. 2012), and a recent Cochrane 
review of pharmacological therapy in AP showed no benefits regarding 
mortality, nor did it find consistent clinical benefits with any intervention 
(Moggia et al. 2017). As already mentioned above, one of the main treatment 
challenges is the narrow time frame between symptom onset, hospital 
admission, and evolution of OD. Therefore, SAP patients without OD on 
admission could serve as a potential patient group for applying immune 
therapy. Another challenge while introducing immune therapy is that pro- and 
anti-inflammatory processes can occur simultaneously early in the course of 
disease, and not only in different compartments of the body, but also in various 
leukocyte subsets (Cavaillon and Annane 2006, Shi et al. 2006, Kasten et al. 
2010). Additionally, we do not yet know which alterations in immune response 
are crucial for the outcome of disease (Venet et al. 2013). Future studies should 
also increase our knowledge regarding the timeframe during which the 
unresponsive cells will spontaneously recover their functions.  
Monitoring a patient’s current immune status could provide crucial 
information while planning the optimal treatment. Studying the 
phosphorylation changes in the signaling pathways of circulating leukocytes 
using whole-blood phosphospecific flow cytometry may bring us one step 
closer to this goal. Theoretically, this method could also be utilized to test the 
effects of a potential therapeutic agent in a whole blood sample of a patient, 
although it must be remembered that circulating leukocytes present only one 
element of the immune response, and it is possible that tissue leukocytes will 
respond differently to ex vivo stimulus (Caldwell and Hotchkiss 2011). In the 
end, it seems that applying an effective and safe immune therapy in the future 
invariably requires the careful immunological characterization of a single 
patient. 
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3.7 CONCLUSIONS 
 
I) Of the 48 evaluated cytokines, IL-8, HGF, and G-CSF serve as 
predictive markers of SAP in AP patients without OD on admission.  
 
II) The value of IL-8 and HGF as predictors of SAP was confirmed in an 
independent cohort of AP patients without OD on admission. IL-8 
may also predict persistent OD in AP patients with OD on 
admission.  
 
II) Circulating nucleosomes predict SAP in AP patients without OD on 
admission.   
 
III) Signaling aberrations of blood leukocytes in sepsis resemble those 
discovered earlier in SAP. Aberrations in STAT1 and STAT3 
pathways, but not in NF-ĸB, may be associated with the severity of 
AP. Aberrations in STAT3 pathway may also be associated with OD. 
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